JP2001026564A - Hydronaphthalene derivative - Google Patents

Hydronaphthalene derivative

Info

Publication number
JP2001026564A
JP2001026564A JP11197344A JP19734499A JP2001026564A JP 2001026564 A JP2001026564 A JP 2001026564A JP 11197344 A JP11197344 A JP 11197344A JP 19734499 A JP19734499 A JP 19734499A JP 2001026564 A JP2001026564 A JP 2001026564A
Authority
JP
Japan
Prior art keywords
group
mmol
added
compound
silica gel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP11197344A
Other languages
Japanese (ja)
Inventor
Akira Takahashi
昭 高橋
Junichi Masuda
順一 増田
Kenichi Tanaka
憲一 田中
Toshiyuki Wakayama
敏之 若山
Nobuaki Koike
信明 小池
Toshiaki Segawa
俊章 瀬川
Shigeo Nozoe
重男 野副
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toagosei Co Ltd
Original Assignee
Toagosei Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toagosei Co Ltd filed Critical Toagosei Co Ltd
Priority to JP11197344A priority Critical patent/JP2001026564A/en
Publication of JP2001026564A publication Critical patent/JP2001026564A/en
Pending legal-status Critical Current

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

PROBLEM TO BE SOLVED: To obtain a new compound having high antifungal activity against fungi causing opportunistic infections diseases, excellent in selectivity, and useful as an antifungal agent or an anticancer agent useful in clinical practices, or as a raw material therefor. SOLUTION: This compound is a compound of formula I (X and Y are each a hydroxyl group wherein a lower alkyl group and a substituent or a protective group may be contained, or a carbonyl group wherein a protective group being in a united form of XY may be contained; (m) and (n) are each <=3), for example, a compound of formula II (THP is tetrahydropyranyl). The compound of formula I is obtained by using sclareolide (Aldrich reagent) as starting material and through a hydronaphthalene having two methyl groups at 4-position, a methyl group and a hydroxy group at 8-position, and a 2-hydroxyethyl group at 9-position, and a methyl group at 10-position, a hydronaphthalene having a methyl group and a hydroxy group at 8-position, a 2-acetoxyethyl group at 9-position, or the like.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、ヒドロナフタレン
環構造を有する新規なヒドロナフタレン誘導体に関する
ものであり、本発明の化合物は抗真菌剤として、あるい
は各種抗真菌剤の原料として、さらにはその他の医薬品
またはその原料として、例えば、抗癌剤として、あるい
は各種抗癌剤の原料としても有効なものであり、本発明
は医薬製造技術に属するものである。
TECHNICAL FIELD The present invention relates to a novel hydronaphthalene derivative having a hydronaphthalene ring structure, and the compound of the present invention is used as an antifungal agent or as a raw material for various antifungal agents, The present invention is also effective as a drug or a raw material thereof, for example, as an anticancer agent, or as a raw material for various anticancer agents, and the present invention belongs to a pharmaceutical manufacturing technique.

【0002】[0002]

【従来の技術】抗生物質を中心に抗微生物薬の開発が目
ざましい発展を遂げるなかで,抗真菌剤に関してはその
種類、有効性や毒性の点から判断して、必ずしも満足で
きる状態にはない。抗真菌剤の治療対象となる真菌症に
は深在性真菌感染症と表在性真菌感染症とがあり、深在
性真菌感染症は、カンジダ症、アスペルギルス症、クリ
プトコッカス症、ムコール症が多く、その他輸入真菌症
を含めて、アクチノミセス症、ノカルジア症、クロモブ
ラストミコーシス、ヒストプラスマ症、コクシジオイデ
ス症、ゲオトリクム症、ペニシリウム症などが知られて
いる。また、表在性真菌症には水虫や爪真菌症、タムシ
などがある。特に、近年、老齢化、手術後、抗癌剤や免
疫抑制剤、ステロイドホルモン等の汎用やエイズ感染等
による生体防御能の低下からカンジダ(Candida)、アス
ペルギルス(Aspergillus)、クリプトコッカス(Cryptoco
ccus)等の真菌感染による日和見感染症が一つの医療問
題になっており、その治療薬の開発が望まれている。こ
れらの真菌感染症の治療薬としては、現在のところ、ア
ンホテリンシB、フルコナゾール、イトラコナゾール、
ミコナゾール、5-フロロシトシンなどの化学療法剤が使
用されている。しかし、これらの化学療法剤は毒性や治
療効果の面で必ずしも満足できるものでなく、また、耐
性菌の出現も問題となっている。この問題を解決するた
めに、選択性に優れた臨床上有用な抗真菌薬が望まれて
いる。
2. Description of the Related Art With the remarkable development of antimicrobial drugs centering on antibiotics, antifungal agents are not always in a satisfactory state, judging from their kind, effectiveness and toxicity. Mycosis to be treated with antifungal agents includes deep fungal infections and superficial fungal infections, and deep fungal infections include candidiasis, aspergillosis, cryptococcosis, and mucormycosis. Actinomycosis, Nocardiosis, Chromoblast Mycosis, Histoplasmosis, Coccidioidomycosis, Geotrichum disease, Penicillium disease, etc., including other imported mycosis. In addition, superficial mycosis includes athlete's foot, onychomycosis, and bugs. In particular, in recent years, aging, after surgery, Candida (Candida), Aspergillus (Aspergillus), Cryptococcus (Cryptoco
Opportunistic infections caused by fungal infections such as ccus) have become a medical problem, and the development of therapeutic agents has been desired. Therapeutic agents for these fungal infections currently include amphotericin B, fluconazole, itraconazole,
Chemotherapeutic agents such as miconazole, 5-fluorocytosine have been used. However, these chemotherapeutic agents are not always satisfactory in terms of toxicity and therapeutic effect, and the emergence of resistant bacteria is also a problem. In order to solve this problem, a clinically useful antifungal drug excellent in selectivity is desired.

【0003】[0003]

【発明が解決しようとする課題】本発明者等は、日和見
感染症を惹起する上述の真菌類に対して強い抗菌力を有
する、すなわち抗真菌剤として、あるいは抗真菌剤製造
のための原料として有効な新規な化合物を見出すべく鋭
意検討を続けたのである。すなわち、本発明は抗真菌剤
や抗癌剤等として、あるいはその原料として有効な新規
な化合物を提供しようとするものである。
SUMMARY OF THE INVENTION The present inventors have a strong antibacterial activity against the above-mentioned fungi which cause opportunistic infections, that is, as an antifungal agent or as a raw material for producing an antifungal agent. They continued their intensive studies to find effective new compounds. That is, an object of the present invention is to provide a novel compound effective as an antifungal agent, an anticancer agent or the like, or as a raw material thereof.

【0004】[0004]

【課題を解決するための手段】本発明者等は上記目的を
達成すべく鋭意研究を行ない、ヒドロナフタレン環構造
が抗真菌作用に大きな影響を及ぼしていること、すなわ
ち、そのヒドロナフタレン環構造を有するアルビカノー
ルおよびそれと類似の構造を有するスクラレオライドお
よびゲラニイル、リナロール等から合成したヒドロナフ
タレン環構造を有する化合物等に各種の置換基を付加し
た新規な化合物が抗真菌剤として、あるいは抗真菌剤製
造のための原料として有効なであることを見出して本発
明を完成したのである。
Means for Solving the Problems The present inventors have made intensive studies to achieve the above-mentioned object, and have found that the hydronaphthalene ring structure has a great influence on the antifungal action, that is, the hydronaphthalene ring structure has Novel compounds obtained by adding various substituents to arbicanol having a hydronaphthalene ring structure synthesized from sclareolide having a structure similar thereto and geraniyl, linalool, etc. as an antifungal agent or producing an antifungal agent The present invention was found to be effective as a raw material for the present invention.

【0005】すなわち、本発明は下記構造式で示される
ヒドロナフタレン誘導体に関するものである。
That is, the present invention relates to a hydronaphthalene derivative represented by the following structural formula.

【0006】[0006]

【化2】 Embedded image

【0007】ただし、式中XとYは低級アルキル基と置
換基または保護基を有していてもよい水酸基であるか、
XYの合一した形の保護基を有していてもよいカルボニ
ル基であり、mとnは3までの整数である。
Wherein X and Y are a lower alkyl group and a hydroxyl group which may have a substituent or a protecting group,
XY is a carbonyl group which may have a combined protective group, and m and n are integers up to 3.

【0008】[0008]

【発明の実施の形態】以下、本発明について詳説する。
本発明における化合物は、その構造の中心がヒドロナフ
タレン環であり、より詳細には前記構造式で示される様
に、その8位に低級アルキル基と置換基または保護基を
有していてもよい水酸基またはカルボニル基またはカル
ボニル基をケタールやアセタール等の保護基で保護した
ものであり、9位にアリルエーテル基を持つアルキル基
を有しているものであり、既知の化合物であるスクラレ
オライド、ゲラニイル、リナロール等から容易に誘導さ
れるものである。水酸基の置換基としては、エーテル又
はエステル構造としての低級アルキル基、低級アルキロ
イル基が、保護基としては、水酸基では、メトキシメチ
ル基(MOM)、メチルチオメチル(MTM)、テトラヒドロピラ
ニル(THP)、t-ブチル(t-Bu)、トリチル(Trt)、ベンジル
(BzlまたはBn)、p-メトキシベンジル(MP)などのエー
テル型保護基、アセチル基などのアシル型保護基、トリ
メチルシリル(TMS)、t-ブチルジメチルシリル(TBDMS)等
のシリル型保護基等が、カルボニル基では、ジメチルケ
タールやエチレンアセタールのようなケタール型、アセ
タール型保護基等の一般に有機合成等に使用される保護
基を挙げることができる。
DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention will be described below in detail.
The compound in the present invention has a hydronaphthalene ring at the center of its structure, and more specifically, may have a lower alkyl group and a substituent or a protecting group at the 8-position, as shown in the structural formula. A hydroxyl group or a carbonyl group or a carbonyl group protected with a protecting group such as a ketal or an acetal, having an alkyl group having an allyl ether group at the 9-position, and a known compound, sclareolide; It is easily derived from geraniyl, linalool and the like. As a substituent of the hydroxyl group, a lower alkyl group as an ether or ester structure, a lower alkyloyl group, as a protecting group, a hydroxyl group, methoxymethyl group (MOM), methylthiomethyl (MTM), tetrahydropyranyl (THP), t-butyl (t-Bu), trityl (Trt), benzyl
(Bzl or Bn), ether-type protecting groups such as p-methoxybenzyl (MP), acyl-type protecting groups such as acetyl groups, and silyl-type protecting groups such as trimethylsilyl (TMS) and t-butyldimethylsilyl (TBDMS). Examples of the carbonyl group include protecting groups generally used in organic synthesis and the like, such as ketal-type and acetal-type protecting groups such as dimethyl ketal and ethylene acetal.

【0009】本発明の化合物は上記の様に末端に不飽和
結合を有しているため、それを利用して各種の化合物を
付加することが出来、また、エポキシ化した後、エポキ
シを利用して各種の化合物を付加することも出来、得ら
れた新規な化合物も抗真菌剤として、あるいは抗真菌剤
製造のための原料として有効なものである。それらの化
合物としては、不飽和結合に水素添加してアルキル基と
した化合物、エポキシ化合物、エポキシに水が付加して
得られるグリコール化合物やこの誘導体、このグリコー
ル化合物から合成したカルボン酸体やアルデヒド体、窒
素化合物が付加したもの例えばトリアゾール付加体、モ
ルホリンやその誘導体やピペリジンやその誘導体、アル
キルアミン、ヒドロキシアルキルアミン、アミノ糖の付
加体、イミダゾール付加体などが挙げられる。
Since the compound of the present invention has an unsaturated bond at the terminal as described above, various compounds can be added by utilizing the unsaturated bond. Various compounds can be added to the compound, and the obtained novel compound is also effective as an antifungal agent or as a raw material for producing an antifungal agent. Examples of such compounds include compounds that have been hydrogenated to unsaturated bonds to form alkyl groups, epoxy compounds, glycol compounds and derivatives thereof obtained by adding water to epoxy, and carboxylic acid and aldehyde compounds synthesized from the glycol compounds. And nitrogen compounds, such as adducts of triazole, morpholine and its derivatives, piperidine and its derivatives, adducts of alkylamines, hydroxyalkylamines, amino sugars, and imidazole adducts.

【0010】[0010]

【実施例】以下に本発明ついての実施例を示すが、この
実施例は何ら本発明を制限するものではない。また、各
実施例における抗真菌活性測定法及び感染治療試験方法
は以下のとおりである。 ○ 抗カンジダアルビカンス(Candida albicans)活性測
定法 各種の化合物について、カンジダアルビカンス(Candida
albicans)を被験菌として、該真菌に対する感受性をin
vitroで試験してその活性を確認した。抗真菌剤感受性
試験は、日本医真菌学会誌 Vol.36(1), 62-64(1995) で
提案されている方法に準じて行った。実験に使用した菌
株は、帝京大学医真菌研究センターから分譲された株T
IMM1768とTIMM3318を用いた。このう
ち、TIMM3318株はアゾール系抗真菌剤に対し耐
性を有しているものである。感受性測定用培地は、RP
MI1640(Irvine Scientific Cat. #9512)を10.
4gと炭酸水素ナトリウムを2.0gを滅菌蒸留水900m
lに溶解後、緩衝液としてMOPS34.53gを加え、
溶解するまでよく撹拌し、次に、水酸化ナトリウムでp
H7.0に修正した後、滅菌蒸留水を加えて1リットル
に容量調整し、濾過滅菌後4℃に保存した。試験菌はYM
agar培地(Difco)を用い、35℃,24〜48時間の培
養を2回以上行って継代した後、5mlの滅菌生理食塩水
に懸濁して得た。この懸濁液の吸光度を600nmで測定
し、あらかじめ作成した検量線から菌量を求め、2×1
3cells/mlの菌数になるように感受性測定用培地で希
釈し、試験菌液とした。試験検体は20%DMSO添加
メタノール溶液を用いて検体を溶かし、2倍段階希釈に
て試験検定溶液を作製した。抗真菌感受性の試験は、9
6ウェルの平底マイクロプレートに90μlの感受性測
定用培地を分注し、10μlの試験検定溶液と100μl
の試験菌液を各ウェルに加え、所定の濃度を作製した。
湿度を保った容器にマイクロプレートを入れ、72時間
を限度として35℃にて培養し、24時間毎に観察して
発育コントロールの濁度が0.2に達した時点で各ウェ
ルの濁度を測定した。80%発育阻止濃度(IC80)の判
定は、マイクロプレートをミキサーで撹拌後、発育コン
トロールの培養液を40μl取り、これに感受性測定用
培地160μlを加え、IC80相当のウェルを作製し
た。このウェルの濁度に比べて同等またはそれ以下の濁
度を示すウェルを終末点とした。
EXAMPLES Examples of the present invention will be described below, but these examples do not limit the present invention in any way. In addition, the antifungal activity measurement method and the infection treatment test method in each Example are as follows. ○ Assay for anti-Candida albicans activity Candida albicans (Candida albicans)
albicans) as a test bacterium, and
Tested in vitro to confirm its activity. The antifungal susceptibility test was performed according to the method proposed in the Journal of the Japanese Society for Medical Mycology, Vol. 36 (1), 62-64 (1995). The strain used for the experiment was strain T, which was distributed by Teikyo University Medical Mycology Research Center.
IMM1768 and TIMM3318 were used. Among them, the TIMM3318 strain has resistance to an azole antifungal agent. The culture medium for sensitivity measurement is RP
MI1640 (Irvine Scientific Cat. # 9512) for 10.
4 g and 2.0 g of sodium bicarbonate in 900 m of sterile distilled water
After dissolving in l, 34.53 g of MOPS was added as a buffer,
Stir well until dissolved, then p with sodium hydroxide
After adjusting to H7.0, the volume was adjusted to 1 liter by adding sterile distilled water, and the solution was sterilized by filtration and stored at 4 ° C. Test bacteria are YM
Using an agar medium (Difco), the cells were subcultured by culturing at 35 ° C. for 24 to 48 hours twice or more, and then suspended in 5 ml of sterile physiological saline. The absorbance of this suspension was measured at 600 nm, the amount of bacteria was determined from a calibration curve created in advance, and 2 × 1
It was diluted with a culture medium for sensitivity measurement so as to have a cell count of 0 3 cells / ml to prepare a test bacterial solution. The test sample was dissolved using a methanol solution containing 20% DMSO, and a test assay solution was prepared by 2-fold serial dilution. The test for antifungal susceptibility was 9
Dispense 90 μl of sensitivity measurement medium into a 6-well flat bottom microplate, add 10 μl of test assay solution and 100 μl
Was added to each well to prepare a predetermined concentration.
The microplate was placed in a container keeping humidity and cultured at 35 ° C. for a maximum of 72 hours. Observation was made every 24 hours, and when the turbidity of the growth control reached 0.2, the turbidity of each well was determined. It was measured. To determine the 80% growth inhibitory concentration (IC 80 ), a microplate was stirred with a mixer, 40 μl of a growth control culture was taken, and 160 μl of a culture medium for sensitivity measurement was added thereto to prepare a well equivalent to IC 80 . The wells exhibiting a turbidity equal to or less than the turbidity of this well were defined as the end points.

【0011】○ 抗アスペルギルスフミガータス(Asper
gillus fumigatus)活性測定法 1.薬液調製法 試験薬剤を秤量し、20%DMSO添加メタノールで薬
剤希釈段階を作製した。 2.感受性測定培地と調製法 RPM11640(Irvine Scientific Cat.#9512)10.4
g、NaHCO3 2.0gを滅菌蒸留水900m1に溶解後、
緩衝液としてMOPS34.53gを加え撹拌し、NaO
HでpH7.0に修正した後1リットルに容量調整し、濾
過滅菌後使用した。 3.接種菌液の調製 試験菌はポテトデキストロース寒天培地(Difco)を用
い、30℃で1週間培養した後、0.05%Tween80
含有滅菌生理食塩水を加え、分生子浮遊液を得た。血球
計算盤を用いて顕微鏡下で分生子数を計測し、測定用培
地で2.5×105cell/mlの菌数に調整した。 4.培養 96穴平底マイクロプレートに90μlの培地を分注
し、1で調製した薬液を10μl、接種菌液を80μl、
alamar blue液20μlを各ウエルに加えた(培地に対し最
終でDMSOが1%、メタノールが4%、alamar blue
が10%、発育コントロールは薬剤不含の同培地とす
る)。乾燥を防ぐため湿潤容器中で30℃にて培養、2
4時間毎に観察し、発育コントロールのOD570が0.6
に達した時点で終末点を判定した。 5.結果の判定 発育コントロールに対する80%発育阻止濃度(IC80)
を終末点としてこれを最小発育阻止濃度とした。具体的
には発育コントロールの測定値の20%値を基準にして
相当するかそれ以下の測定値を示すものの薬剤濃度をI
80(MIC)とした。
○ Anti-Aspergillus fumigatus (Asper
gillus fumigatus) activity measurement method Drug solution preparation method The test drug was weighed, and a drug dilution step was prepared with methanol containing 20% DMSO. 2. Sensitivity measurement medium and preparation method RPM11640 (Irvine Scientific Cat. # 9512) 10.4
g, 2.0 g of NaHCO 3 in 900 ml of sterile distilled water
34.53 g of MOPS was added as a buffer solution, and the mixture was stirred.
After adjusting the pH to 7.0 with H, the volume was adjusted to 1 liter and sterilized by filtration before use. 3. Preparation of Inoculated Bacterial Solution Test bacteria were cultured on a potato dextrose agar medium (Difco) at 30 ° C. for 1 week, and then 0.05% Tween80 was added.
A sterile physiological saline solution was added to obtain a conidia suspension. The number of conidia was counted under a microscope using a hemocytometer and adjusted to 2.5 × 10 5 cells / ml in a measurement medium. 4. Culture 90 μl of medium was dispensed into a 96-well flat bottom microplate, 10 μl of the drug solution prepared in 1 and 80 μl of the inoculum were added.
20 μl of alamar blue solution was added to each well (final 1% DMSO, 4% methanol, alamar blue
Is 10%, and the growth control is the same medium without drug). Incubate at 30 ° C in a wet container to prevent drying, 2
Observed every 4 hours, OD 570 of the growth control was 0.6.
The end point was judged when reaching. 5. Judgment of results 80% growth inhibitory concentration (IC 80 ) relative to growth control
This was defined as the minimum inhibitory concentration with the endpoint as the endpoint. More specifically, the drug concentration was determined to be equal to or less than 20% of the measured value of the growth control, but the drug concentration was calculated as I
C 80 (MIC).

【0012】〇 感染治療試験 健康に生育したマウス(ICR,4週齢,雌,19〜2
2g,日本チャールスリバー)に対し、0.1%Tween8
0添加した生理食塩水に懸濁したアスペルギルスフミガ
ータス(1.0×106CFU/マウス)の菌液を0.2ml
尾静脈より接種し、感染を成立させた。治療は、5%ア
ラビアゴム水溶液に検体を溶解又は懸濁し、各回0.2m
l量を胃ゾンデを用いて経口投与した(50mg/kgと10m
g/kg又は10mg/kgと2mg/kg)。1回目は菌接種1時間
後に、その後は1日1回24時間おきに6回の投与を行
なった(1回/日,計7日間投与)。対照群は基剤だけを
0.2ml量投与した。薬効は対照動物群が全て死亡した
時点の検体投与群のマウス生存匹数から下記の様に判定
した。 有効 60%以上の生存率 やや有効 40%の生存率 無効 20%以下の生存率
(2) Infection treatment test Healthy growing mice (ICR, 4 weeks old, female, 19-2)
2g, Charles River Japan) 0.1% Tween8
0.2 ml of a bacterial solution of Aspergillus fumigatus (1.0 × 10 6 CFU / mouse) suspended in physiological saline to which 0 was added.
Inoculation was performed through the tail vein to establish infection. Treatment is performed by dissolving or suspending the specimen in a 5% gum arabic aqueous solution, 0.2 m each time.
l was orally administered using a gastric probe (50 mg / kg and 10 m
g / kg or 10 mg / kg and 2 mg / kg). The first administration was performed 1 hour after inoculation of the bacteria, and thereafter, 6 administrations were performed once a day every 24 hours (administered once a day for a total of 7 days). The control group received 0.2 ml of the vehicle alone. The efficacy was determined as follows from the number of surviving mice in the sample administration group at the time when all the control animal groups died. Effective 60% or more survival rate Slightly effective 40% survival rate Ineffective 20% or less survival rate

【0013】実施例1 〇 HAL−3の合成 市販のスクラレオライド(1.25g:5.00mmol、アル
ドリッチ試薬)をテトラヒドロフラン(以下THFとい
う)(10ml)-エーテル(10ml)の混液に溶解し、氷冷下
撹拌しながら水素化リチウムアルミニウム(190mg:
5.00mmol)を少量ずつ加えた。同温下1時間撹拌した
後、酢酸エチルを少量ずつ加え過剰の試薬を分解した。
1N塩酸(40ml)を加えた後酢酸エチル(40ml)で2回
抽出し、抽出液は飽和炭酸水素ナトリウム水溶液及び飽
和食塩水で順次洗浄した。抽出液を無水硫酸マグネシウ
ムで乾燥後溶媒を留去し、析出する結晶を濾取して、4
位に2個のメチル基、8位にメチル基とヒドロキシ基、
9位に2-ヒドロキシエチル基、10位にメチル基を有す
るヒドロナフタレン(以下AT-1という)1.20gを無色
針状晶として得た(以下構造式の説明において、格別の
注釈がなければ4位と10位のメチル基については説明
を省略する)。その1H-NMRスペクトル(400MHz)は以下の
とおりであった。 (CDCl3,ppm): 0.79(3H,s,Me-C10), 0.79(3H,s,Meβ-C
4), 0.88(3H,s,Meα-C4),1.20(3H,s,Me-C8), 1.90(1H,d
dd,J=12.2,3.4,2.9,H7),3.46(1H,ddd,J=10.3,8.3,5.9,H
12), 3.75(1H,ddd,J=10.3,4.4,4.4,H12')
Example 1 Synthesis of HAL-3 A commercially available sclareolide (1.25 g: 5.00 mmol, Aldrich reagent) was dissolved in a mixture of tetrahydrofuran (hereinafter referred to as THF) (10 ml) -ether (10 ml). Lithium aluminum hydride (190 mg:
5.00 mmol) was added in small portions. After stirring at the same temperature for 1 hour, ethyl acetate was added little by little to decompose excess reagent.
After adding 1N hydrochloric acid (40 ml), the mixture was extracted twice with ethyl acetate (40 ml), and the extract was washed successively with a saturated aqueous solution of sodium hydrogen carbonate and a saturated saline solution. After the extract was dried over anhydrous magnesium sulfate, the solvent was distilled off, and the precipitated crystals were collected by filtration.
Two methyl groups at the 8 position, a methyl group and a hydroxy group at the 8 position,
1.20 g of hydronaphthalene having a 2-hydroxyethyl group at the 9-position and a methyl group at the 10-position (hereinafter referred to as AT-1) was obtained as colorless needles (unless otherwise noted in the description of the structural formula, The description of the methyl groups at the 4- and 10-positions is omitted. Its 1 H-NMR spectrum (400 MHz) was as follows. (CDCl 3 , ppm): 0.79 (3H, s, Me-C10), 0.79 (3H, s, Meβ-C
4), 0.88 (3H, s, Meα-C4), 1.20 (3H, s, Me-C8), 1.90 (1H, d
dd, J = 12.2,3.4,2.9, H7), 3.46 (1H, ddd, J = 10.3,8.3,5.9, H
12), 3.75 (1H, ddd, J = 10.3,4.4,4.4, H12 ')

【0014】上記AT-1(1.20g:4.72mmol)のピ
リジン(1.5ml)溶液に氷冷下無水酢酸(1ml)を加えた
後、室温下一晩放置した。反応液に氷水(40ml)を加え
酢酸エチル(30ml)で2回抽出した後、抽出液を1N塩
酸、飽和炭酸水素ナトリウム水溶液及び飽和食塩水で順
次洗浄した。抽出液を無水硫酸マグネシウムで乾燥後、
溶媒を留去して得られる残渣をシリカゲルカラムクロマ
トグラフィー[13g:1.5cmIDx16.5、溶出溶媒:
クロロホルムー酢酸エチル=100/0→70/30]に
より精製して、8位にメチル基とヒドロキシ基、9位に
2-アセトキシエチル基を有するヒドロナフタレン(以下
AT-2という)1.35gを無色飴状物質として得た。そ
1H-NMRスペクトル(400MHz)は以下のとおりであった。 (CDCl3,ppm): 0.79(3H,s,Me-C10), 0.79(3H,s,Meβ-C
4), 0.87(3H,s,Meα-C4),1.16(3H,s,Me-C8), 1.89(1H,d
dd,J=12.2,2.9,2.9,H7), 4.12 (2H,m,H12 and H12')
Acetic anhydride (1 ml) was added to a solution of AT-1 (1.20 g: 4.72 mmol) in pyridine (1.5 ml) under ice-cooling, and the mixture was allowed to stand at room temperature overnight. Ice water (40 ml) was added to the reaction solution, and the mixture was extracted twice with ethyl acetate (30 ml). The extract was washed successively with 1N hydrochloric acid, a saturated aqueous solution of sodium hydrogencarbonate and saturated saline. After drying the extract over anhydrous magnesium sulfate,
The residue obtained by evaporating the solvent was subjected to silica gel column chromatography [13 g: 1.5 cm ID × 16.5, elution solvent:
Chloroform-ethyl acetate = 100/0 → 70/30], and methyl and hydroxy groups at the 8th position and 9th position
1.35 g of hydronaphthalene having a 2-acetoxyethyl group (hereinafter referred to as AT-2) was obtained as a colorless candy substance. Its 1 H-NMR spectrum (400 MHz) was as follows. (CDCl 3 , ppm): 0.79 (3H, s, Me-C10), 0.79 (3H, s, Meβ-C
4), 0.87 (3H, s, Meα-C4), 1.16 (3H, s, Me-C8), 1.89 (1H, d
dd, J = 12.2,2.9,2.9, H7), 4.12 (2H, m, H12 and H12 ')

【0015】上記AT-2の17.0mmol:5.1gを20
0mlのナス型フラスコに入れジクロロメタン50mlにて
溶解させた。氷冷下攪拌しながら3,4-ジヒドロ-2H-ピラ
ン(和光純薬株式会社製)25.5mmol(2.3ml)を滴下
し、p-トルエンスルホン酸ピリジニウム(和光純薬株式
会社製)1.7mmol(425mg)を加えた。反応液を室温に
戻した後18時間攪拌を行った。18時間後反応液に蒸
留水20mlおよびクロロホルム10mlを加えて抽出を行
い、クロロホルム層を1N-塩酸20ml、飽和炭酸水素ナ
トリウム水溶液20ml、飽和食塩水20mlにて順次洗浄
後、無水硫酸マグネシウムにて乾燥させた。これを濾過
減圧下留去し、残渣をシリカゲルカラムクロマトグラフ
ィー(3.0cmID×13.0cm、溶出液:ヘキサン/酢酸エ
チル=100/0〜50/50)にて分画することにより
得たヘキサン/酢酸エチル=90/10〜80/20溶出
画分5.5gを200mlのナス型フラスコに移しエタノー
ル50mlにて溶解させた。氷冷下攪拌しながら1N-水酸
化ナトリウム水50mlを加えた後、反応液を室温に戻し
て2時間攪拌を行った。2時間後反応液を減圧下濃縮す
ることによりエタノールを除いた後、酢酸エチル50ml
にて2回抽出を行った。抽出液を蒸留水20ml、飽和食
塩水20mlにて順次洗浄後無水硫酸マグネシウムにて乾
燥させた。これを濾過減圧下留去し、残渣をシリカゲル
カラムクロマトグラフィー(3.0cmID×14.0cm、溶
出液:ヘキサン/酢酸エチル=100/0〜50/50)に
て分画することにより、ヘキサン/酢酸エチル=70/3
0〜50/50溶出画分として下記構造式で示される化
合物(以下HAL-1という)の無色柱状結晶4.6g得た。
その特性は下記のとおりであり、1H-NMRスペクトル(400
MHz:CDCl3)チャートを図1、13C-NMRスペクトル(400MH
z:CDCl3)チャートを図2として示す。 Rf値:シリカゲル薄層クロマトグラフィー:0.75
[シリカゲル60F254(メルク)、展開溶媒:クロロホル
ム/メタノール=20/1]、0.24[RP−18F254s
(メルク)、展開溶媒:90%メタノール] 呈色反応:エールリッヒ試薬陽性(茶色)、アニスアルデ
ヒド試薬陽性(緑褐色)、50%硫酸試薬陽性(黒色)
17.0 mmol of the above AT-2: 5.1 g was added to 20
The mixture was placed in a 0 ml eggplant-shaped flask and dissolved with 50 ml of dichloromethane. While stirring under ice cooling, 2,4-dihydro-2H-pyran (manufactured by Wako Pure Chemical Industries, Ltd.) (25.5 mmol, 2.3 ml) was added dropwise, and pyridinium p-toluenesulfonate (manufactured by Wako Pure Chemical Industries, Ltd.) 1 0.7 mmol (425 mg) was added. After the temperature of the reaction solution was returned to room temperature, stirring was performed for 18 hours. After 18 hours, the reaction solution was extracted by adding 20 ml of distilled water and 10 ml of chloroform, and the chloroform layer was successively washed with 20 ml of 1N hydrochloric acid, 20 ml of a saturated aqueous solution of sodium hydrogen carbonate and 20 ml of a saturated saline solution, and dried over anhydrous magnesium sulfate. I let it. This was distilled off under reduced pressure by filtration, and the residue was fractionated by silica gel column chromatography (3.0 cm ID × 13.0 cm, eluent: hexane / ethyl acetate = 100/0 to 50/50) to obtain hexane. 5.5 g of the fraction eluted with 90/10 to 80/20 / ethyl acetate was transferred to a 200 ml eggplant-shaped flask and dissolved in 50 ml of ethanol. After adding 1N-sodium hydroxide aqueous solution (50 ml) with stirring under ice cooling, the reaction solution was returned to room temperature and stirred for 2 hours. After 2 hours, the reaction solution was concentrated under reduced pressure to remove ethanol, and then 50 ml of ethyl acetate was added.
The extraction was performed twice. The extract was washed successively with 20 ml of distilled water and 20 ml of saturated saline and dried over anhydrous magnesium sulfate. This was distilled off under reduced pressure by filtration, and the residue was fractionated by silica gel column chromatography (3.0 cm ID × 14.0 cm, eluent: hexane / ethyl acetate = 100/0 to 50/50) to give hexane / hexane. Ethyl acetate = 70/3
As a fraction eluted with 0 to 50/50, 4.6 g of colorless columnar crystals of a compound represented by the following structural formula (hereinafter referred to as HAL-1) were obtained.
Its properties are as follows, 1 H-NMR spectrum (400
MHz: CDCl 3 ) chart as shown in FIG. 1, 13 C-NMR spectrum (400 MHz
The z: CDCl3) chart is shown in FIG. Rf value: silica gel thin layer chromatography: 0.75
[Silica gel 60F254 (Merck), developing solvent: chloroform / methanol = 20/1], 0.24 [RP-18F254s
(Merck), developing solvent: 90% methanol] Color reaction: Positive for Ehrlich reagent (brown), positive for anisaldehyde reagent (greenish brown), positive for 50% sulfuric acid reagent (black)

【0016】[0016]

【化3】 Embedded image

【0017】水素化ナトリウム8.8mmol(352mg)を
乾燥させた100mlの二口フラスコに秤取り、フラスコ
内を窒素置換後、氷冷下脱水DMF6.0mlを注入し、
さらにHAL-1の4.4mmol(1500mg)を脱水DMF
6.0mlに溶解して注入した。反応液を室温下30分間
攪拌後、氷冷下臭化アリル(和光純薬株式会社製)8.8m
mol(750μl)を注入した。その後室温下20時間攪拌
を行った。20時間後反応液に蒸留水20mlを加えた後
酢酸エチル30mlにて2回抽出を行い、抽出液を蒸留
水、飽和食塩水5mlにて順次洗浄後無水硫酸マグネシウ
ムにて乾燥させた。乾燥後濾過減圧下溶媒を留去し、残
渣をシリカゲルカラムクロマトグラフィー(2.0cmID×
18.0cm、溶出液:ヘキサン/酢酸エチル=100/0
〜20/80)にて分画することにより、ヘキサン/酢酸
エチル=90/10溶出画分として下記構造式で示され
る本発明の化合物(以下HAL-3という)の無色油状物1
300mg得た。その特性は下記のとおりであり、1H-NMR
スペクトル(400MHz:CDCl3)チャートを図3、13C-NMRス
ペクトル(400MHz:CDCl3)チャートを図4として示す。 Rf値:シリカゲル薄層クロマトグラフィー:0.85
[シリカゲル60F254(呈色反応:エールリッヒ試薬陽
性(茶色)、アニスアルデヒド試薬陽性(紫色)、50%硫
酸試薬陽性(黒色)
8.8 mmol (352 mg) of sodium hydride was weighed into a dried 100 ml two-necked flask, and the flask was purged with nitrogen, and then 6.0 ml of dehydrated DMF was poured under ice cooling.
Further, 4.4 mmol (1500 mg) of HAL-1 was dehydrated in DMF.
Dissolved in 6.0 ml and injected. After the reaction solution was stirred at room temperature for 30 minutes, allyl bromide (manufactured by Wako Pure Chemical Industries, Ltd.) 8.8 m under ice cooling.
mol (750 μl) was injected. Thereafter, the mixture was stirred at room temperature for 20 hours. After 20 hours, 20 ml of distilled water was added to the reaction solution, and the mixture was extracted twice with 30 ml of ethyl acetate. The extract was washed successively with 5 ml of distilled water and 5 ml of saturated saline, and dried over anhydrous magnesium sulfate. After drying, the solvent was removed under reduced pressure by filtration, and the residue was subjected to silica gel column chromatography (2.0 cmID ×
18.0 cm, eluent: hexane / ethyl acetate = 100/0
Hexane / ethyl acetate = 90/10 to give a colorless oil 1 of the compound of the present invention (hereinafter referred to as HAL-3) represented by the following structural formula as a fraction eluted with 90/10.
300 mg were obtained. Its properties are as follows, 1 H-NMR
Spectrum (400 MHz: CDCl 3) FIG chart 3, 13 C-NMR spectrum: showing a (400 MHz CDCl 3) chart as FIG. Rf value: silica gel thin layer chromatography: 0.85
[Silica gel 60F254 (color reaction: Ehrlich reagent positive (brown), anisaldehyde reagent positive (purple), 50% sulfuric acid reagent positive (black)

【0018】[0018]

【化4】 Embedded image

【0019】応用例1 〇 HAL-4の合成 HAL-3の1.8mmol(700mg)を30mlのナス型フラ
スコに秤取り、アセトン5ml、蒸留水2mlを加えた後氷
冷下N-メチルモルフォリン-N-オキシド(東京化成株式会
社製:50%水溶液)3.3mmol(780μl)および2%オ
スミウム酸溶液50μlを加えた。その後室温下20時
間攪拌を行った。20時間後反応液に10%亜硫酸水素
ナトリウム水溶液5mlを加えさらに20分間攪拌を行っ
た。これに蒸留水5mlを加えた後酢酸エチル10mlにて
2回抽出を行い、抽出液を蒸留水、飽和食塩水にて順次
洗浄後無水硫酸マグネシウムにて乾燥させた。乾燥後濾
過減圧下溶媒を留去し、残渣をシリカゲルカラムクロマ
トグラフィー(2.0cmID×15.0cm、溶出液:クロロ
ホルム/メタノール=100/1〜100/10)にて分画
することにより、クロロホルム/メタノール=100/3
〜100/5溶出画分として下記構造式で示される化合
物(以下HAL-4という)の無色油状物756mg得た。そ
の特性は下記のとおりであり、1H-NMRスペクトル(400MH
z:CDCl3)チャートを図5として示す。 Rf値:シリカゲル薄層クロマトグラフィー:0.60
[シリカゲル60F254(メルク)、展開溶媒:クロロホル
ム/メタノール=10/1]、0.36[シリカゲル60F2
54(メルク)、展開溶媒:ヘキサン/酢酸エチル=1/
4]、0.23[RP−18F254s(メルク)、展開溶媒:
90%メタノール] 呈色反応:エールリッヒ試薬陽性(紫色)、アニスアルデ
ヒド試薬陽性(黄緑色)、50%硫酸試薬陽性(紫色)
Application Example 1 Synthesis of HAL-4 1.8 mmol (700 mg) of HAL-3 was weighed into a 30 ml eggplant-shaped flask, 5 ml of acetone and 2 ml of distilled water were added, and then N-methylmorpholine was added under ice cooling. 3.3 mmol (780 μl) of -N-oxide (manufactured by Tokyo Chemical Industry Co., Ltd .: 50% aqueous solution) and 50 μl of a 2% osmic acid solution were added. Thereafter, the mixture was stirred at room temperature for 20 hours. After 20 hours, 5 ml of a 10% aqueous sodium bisulfite solution was added to the reaction solution, and the mixture was further stirred for 20 minutes. After adding 5 ml of distilled water thereto, extraction was performed twice with 10 ml of ethyl acetate. The extract was washed with distilled water and saturated saline in this order, and dried over anhydrous magnesium sulfate. After drying, the solvent is distilled off under reduced pressure under filtration, and the residue is fractionated by silica gel column chromatography (2.0 cm ID × 15.0 cm, eluent: chloroform / methanol = 100/1 to 100/10) to give chloroform. / Methanol = 100/3
756 mg of a colorless oil of a compound represented by the following structural formula (hereinafter referred to as HAL-4) was obtained as a 100100/5 eluted fraction. Its properties are as follows, 1 H-NMR spectrum (400 MH
The z: CDCl 3 ) chart is shown in FIG. Rf value: silica gel thin layer chromatography: 0.60
[Silica gel 60F254 (Merck), developing solvent: chloroform / methanol = 10/1], 0.36 [silica gel 60F2
54 (Merck), developing solvent: hexane / ethyl acetate = 1 /
4], 0.23 [RP-18F254s (Merck), developing solvent:
90% methanol] Color reaction: Positive for Ehrlich reagent (purple), positive for anisaldehyde reagent (yellowish green), positive for 50% sulfuric acid reagent (purple)

【0020】[0020]

【化5】 Embedded image

【0021】応用例2 〇 HAL-5の合成 過ヨウ素酸ナトリウム1.6mmol(340mg)を50mlの
ナス型フラスコに秤取り、室温下蒸留水3.5mlおよび
HAL-4の1.1mmol(435mg)を3.5mlのアセトンに
溶解して加え、室温下5時間攪拌を行った。5時間後反
応液を減圧下濃縮することによりアセトンを除き、蒸留
水3mlを加え、酢酸エチル8mlにて2回抽出を行った。
抽出液を蒸留水、飽和食塩水にて順次洗浄後無水硫酸マ
グネシウムにて乾燥させた。乾燥後濾過減圧下溶媒を留
去し、下記構造式で示される化合物(以下HAL-4Aとい
う)327mg得た。これを50mlのフラスコに入れ、氷
冷下アセトン4ml、ジョーンズ試薬(2.67mmol/ml)
1.7mmol(636μl)を加え1時間攪拌を行った。1時
間後、反応液が緑色を呈するまでイソプロピルアルコー
ルを加えた後セライトを適量加え、さらにジエチルエー
テル30mlを加えセライトを濾取後、濾液を蒸留水、飽
和食塩水にて順次洗浄後無水硫酸マグネシウムにて乾燥
させた。乾燥後濾過減圧下溶媒を留去し、残渣をシリカ
ゲルカラムクロマトグラフィー(1.5cmID×15.0c
m、溶出液:クロロホルム/メタノール=100/1〜0/
100)にて分画することにより、クロロホルム/メタノ
ール=100/10〜100/50溶出画分として、8位
にメチル基とヒドロキシ基、9位に(2-カルボキシメト
キシ)エチル基を有するヒドロナフタレン(以下HAL-5
という)の無色油状物176mg得た。その特性は下記の
とおりであり、1H-NMRスペクトル(400MHz:CDCl3)チャー
トを図6として示す。 Rf値:シリカゲル薄層クロマトグラフィー:0.20
[シリカゲル60F254(メルク)、展開溶媒:クロロホル
ム/メタノール=5/1]、0.36[RP−18F254s(メ
ルク)、展開溶媒:90%メタノール] 呈色反応:エールリッヒ試薬陽性(紫色)/アニスアルデ
ヒド試薬陽性(紫色)/50%硫酸試薬陽性(紫色)
Application Example 2 Synthesis of HAL-5 1.6 mmol (340 mg) of sodium periodate was weighed into a 50 ml eggplant-shaped flask, and 3.5 ml of distilled water and 1.1 mmol (435 mg) of HAL-4 at room temperature. Was dissolved in 3.5 ml of acetone, and the mixture was stirred at room temperature for 5 hours. After 5 hours, the reaction solution was concentrated under reduced pressure to remove acetone, 3 ml of distilled water was added, and the mixture was extracted twice with 8 ml of ethyl acetate.
The extract was washed successively with distilled water and saturated saline, and dried over anhydrous magnesium sulfate. After drying, the solvent was distilled off under reduced pressure under filtration to obtain 327 mg of a compound represented by the following structural formula (hereinafter referred to as HAL-4A). This was put in a 50 ml flask, and 4 ml of acetone and Jones reagent (2.67 mmol / ml) were added under ice cooling.
1.7 mmol (636 μl) was added, and the mixture was stirred for 1 hour. One hour later, isopropyl alcohol was added until the reaction solution turned green, an appropriate amount of celite was added, 30 ml of diethyl ether was further added, and the celite was collected by filtration. The filtrate was washed with distilled water and saturated saline in that order, and then dried over anhydrous magnesium sulfate. And dried. After drying, the solvent was removed by filtration under reduced pressure and the residue was subjected to silica gel column chromatography (1.5 cm ID × 15.0 c).
m, eluent: chloroform / methanol = 100/1 to 0 /
Chloroform / methanol = 100/10 to 100/50 as a fraction eluted with hydronaphthalene having a methyl group and a hydroxy group at the 8-position and a (2-carboxymethoxy) ethyl group at the 9-position (Hereinafter HAL-5
176 mg of a colorless oil. The characteristics are as follows, and a 1 H-NMR spectrum (400 MHz: CDCl 3 ) chart is shown in FIG. Rf value: silica gel thin layer chromatography: 0.20
[Silica gel 60F254 (Merck), developing solvent: chloroform / methanol = 5/1], 0.36 [RP-18F254s (Merck), developing solvent: 90% methanol] Color reaction: Ehrlich reagent positive (purple) / anisaldehyde Reagent positive (purple) / 50% sulfuric acid reagent positive (purple)

【0022】[0022]

【化6】 Embedded image

【0023】○ 化合物の特性測定 実施例1、応用例1、2で合成された各化合物の抗真菌
活性及び感染治療試験の結果を表1、表2に示す。
測定 Measurement of the properties of the compounds Tables 1 and 2 show the results of the antifungal activity and the infection treatment test of each compound synthesized in Example 1, Application Examples 1 and 2.

【0024】[0024]

【表1】 [Table 1]

【0025】[0025]

【表2】 [Table 2]

【0026】実施例2 ○ ALB−303の合成 テトラヘドロン(Tetrahedron, 1995, 51, 8333-8338)の
記載に従って、(±)-(1'α,4'aα,8'aβ)-Octahydro-
5', 5',8'a-trimethyl-spiro-[1,3-dioxolane-2,2'(1H)
-naphthalene]-1'-methanol(以下ALB302という)を調
製した。その1H-NMR(400MHz)スペクトルデータは以下の
とおりである。 (CDCl3,ppm): 4.09-4.02(2H,m), 3.96-3.84(2H,m), 3.8
4(1H,dd,J=7.8,3.3Hz),3.61(1H,d,J=11.2Hz), 1.96-1.1
1(11H,m), 0.97(1H,dd,J=11.7,3.3Hz), 0.88(3H,s), 0.
86(3H,s), 0.82(3H,s).
Example 2 Synthesis of ALB-303 According to the description of tetrahedron (Tetrahedron, 1995, 51, 8333-8338), (±)-(1′α, 4′aα, 8′aβ) -Octahydro-
5 ', 5', 8'a-trimethyl-spiro- [1,3-dioxolane-2,2 '(1H)
-naphthalene] -1'-methanol (hereinafter referred to as ALB302) was prepared. The 1 H-NMR (400 MHz) spectrum data is as follows. (CDCl 3 , ppm): 4.09-4.02 (2H, m), 3.96-3.84 (2H, m), 3.8
4 (1H, dd, J = 7.8,3.3Hz), 3.61 (1H, d, J = 11.2Hz), 1.96-1.1
1 (11H, m), 0.97 (1H, dd, J = 11.7,3.3Hz), 0.88 (3H, s), 0.
86 (3H, s), 0.82 (3H, s).

【0027】ALB302の4.00g(14.9mmol)を窒素
雰囲気下THF80mlに溶解し、氷冷下60%水素化ナ
トリウム/流動パラフィン1.49g(37.3mmol)を加え
た後、室温で30分間攪拌した。氷冷下、反応液にヨウ
化アリル3.41ml(37.3mmol)を加え、室温で一晩攪
拌した。反応液に飽和塩化アンモニウム水溶液を80ml
加え、更に酢酸エチルを加えた。有機層を飽和食塩水で
3回洗浄し、無水硫酸ナトリウムで乾燥後、減圧下溶媒
留去した。得られた残渣をシリカゲルカラムクロマトグ
ラフィー(酢酸エチル/ヘキサン=2/98〜4/96)で
精製し、本発明の化合物である8位(上記テトラヘドロ
ンにおける化合物名に従うと2'位であるが,以下8位
とする)にエチレンアセタール基、9位(上記テトラヘド
ロンにおける化合物名に従うと1'位であるが,以下9
位とする)にアリルオキシメチル基を有するヒドロナフ
タレン(以下ALB303という)2.28g(収率:50%)
を油状物質として得た。その1H-NMR(400MHz)スペクトル
データは以下のとおりである。 (CDCl3,ppm): 5.90(1H,dddd,J=17.1,10.3,4.4,2.9Hz),
5.50(1H,dd,J=17.1,1.5Hz), 5.14(1H,dd,J=10.3,1.5H
z), 4.00-3.80(6H,m), 3.46(1H,dd,J=10.3,2.9Hz), 3.4
0(1H,dd,J=10.3,4.4Hz), 1.91-1.37(9H,m), 1.20-1.09
(2H,m), 0.96(1H,dd,J=11.7,2.4Hz), 0.92(3H,s), 0.88
(3H,s), 0.83(3H,s).
4.00 g (14.9 mmol) of ALB302 was dissolved in 80 ml of THF under a nitrogen atmosphere, and 1.49 g (37.3 mmol) of 60% sodium hydride / liquid paraffin was added under ice cooling, followed by 30 minutes at room temperature. Stirred. Under ice-cooling, 3.41 ml (37.3 mmol) of allyl iodide was added to the reaction solution, and the mixture was stirred at room temperature overnight. 80 ml of saturated aqueous ammonium chloride solution
In addition, ethyl acetate was further added. The organic layer was washed three times with a saturated saline solution, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue is purified by silica gel column chromatography (ethyl acetate / hexane = 2/98 to 4/96), and the compound of the present invention is in the 8-position (2'-position according to the compound name in tetrahedron). , Hereinafter referred to as 8th position), an ethylene acetal group, and 9th position (1 ′ position according to the compound name in tetrahedron,
2.28 g (hereinafter referred to as ALB303) having an allyloxymethyl group at the same position (yield: 50%)
Was obtained as an oil. The 1 H-NMR (400 MHz) spectrum data is as follows. (CDCl 3 , ppm): 5.90 (1H, dddd, J = 17.1,10.3,4.4,2.9Hz),
5.50 (1H, dd, J = 17.1,1.5Hz), 5.14 (1H, dd, J = 10.3,1.5H
z), 4.00-3.80 (6H, m), 3.46 (1H, dd, J = 10.3,2.9Hz), 3.4
0 (1H, dd, J = 10.3,4.4Hz), 1.91-1.37 (9H, m), 1.20-1.09
(2H, m), 0.96 (1H, dd, J = 11.7,2.4Hz), 0.92 (3H, s), 0.88
(3H, s), 0.83 (3H, s).

【0028】応用例3 〇 ALB304の合成 ALB303の8.88g(28.8mmol)をクロロホルム25
0mlに溶解し、70%3-クロロ過安息香酸10.7g(4
3.4mmol)を加え、20時間攪拌した。反応液を飽和炭
酸水素ナトリウム水溶液で3回、飽和食塩水で1回洗浄
し、有機層を無水硫酸ナトリウムで乾燥後、減圧下溶媒
留去した。得られた残渣をシリカゲルカラムクロマトグ
ラフィー(SiO2:500ml,酢酸エチル/ヘキサン=1
6/84)で精製し、8位にエチレンアセタール基、9位
に(2,3-エポキシプロピル)オキシメチル基を有するヒド
ロナフタレン(以下ALB304という)7.22g(収率:7
7%)を油状物質として得た。その1H-NMR(400MHz)スペ
クトルデータは以下のとおりである。 (CDCl3,ppm): 4.02-3.81(4H,m), 3.70-3.31(4H,m), 3.1
5-3.11(1H,m), 2.78-2.76(1H,m), 2.61-2.58(1H,m), 1.
92-1.37(8H,m), 1.21-0.91(7H,m), 0.88(3H,s),0.83(3
H,s).
Application Example 3 Synthesis of ALB304 8.88 g (28.8 mmol) of ALB303 was added to chloroform 25.
Dissolved in 0 ml and 10.7 g of 70% 3-chloroperbenzoic acid (4
(3.4 mmol) and stirred for 20 hours. The reaction solution was washed three times with a saturated aqueous solution of sodium hydrogen carbonate and once with a saturated saline solution. The organic layer was dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The resulting residue was subjected to silica gel column chromatography (SiO 2 : 500 ml, ethyl acetate / hexane = 1).
6/84), and 7.22 g of hydronaphthalene (hereinafter referred to as ALB304) having an ethylene acetal group at the 8-position and a (2,3-epoxypropyl) oxymethyl group at the 9-position (yield: 7
7%) as an oil. The 1 H-NMR (400 MHz) spectrum data is as follows. (CDCl 3 , ppm): 4.02-3.81 (4H, m), 3.70-3.31 (4H, m), 3.1
5-3.11 (1H, m), 2.78-2.76 (1H, m), 2.61-2.58 (1H, m), 1.
92-1.37 (8H, m), 1.21-0.91 (7H, m), 0.88 (3H, s), 0.83 (3
H, s).

【0029】応用例4 〇 ALB305の合成 ALB304の6.72g(20.7mmol)をジオキサン160
mlに溶解し、2N水酸化ナトリウム160mlを加え、8
時間加熱環流した。反応液を氷冷後、2N塩酸160ml
を加え、クロロホルムで3回抽出した。有機層を合わ
せ、無水硫酸ナトリウムで乾燥後、減圧下溶媒留去し
た。得られた残渣をシリカゲルカラムクロマトグラフィ
ー(SiO2:500ml,酢酸エチル/ヘキサン=67/2
3〜0/100)で精製し、8位にエチレンアセタール
基、9位に(2,3-ジヒドロキシプロピル)オキシメチル基
を有するヒドロナフタレン(以下ALB305という)5.6
0g(収率:79%)を油状物質として得た。その1H-NMR
(400MHz)スペクトルデータは以下のとおりである。 (CDCl3,ppm): 4.03-3.78(5H,m), 3.72-3.44(6H,m), 1.9
3-1.91(1H,m), 1.78-1.75(1H,m), 1.67-0.95(10H,m),
0.88(6H,s), 0.82(3H,s)
Application Example 4 Synthesis of ALB305 6.72 g (20.7 mmol) of ALB304 was added to dioxane 160
dissolved in 2 ml of sodium hydroxide and added 160 ml of 2N sodium hydroxide.
Reflux with heating for hours. After cooling the reaction solution on ice, 2N hydrochloric acid 160 ml
And extracted three times with chloroform. The organic layers were combined, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was subjected to silica gel column chromatography (SiO 2 : 500 ml, ethyl acetate / hexane = 67/2).
3 to 0/100), and hydronaphthalene having an ethylene acetal group at the 8-position and a (2,3-dihydroxypropyl) oxymethyl group at the 9-position (hereinafter referred to as ALB305) 5.6.
0 g (yield: 79%) was obtained as an oil. Part 1 H-NMR
The (400 MHz) spectrum data is as follows. (CDCl 3 , ppm): 4.03-3.78 (5H, m), 3.72-3.44 (6H, m), 1.9
3-1.91 (1H, m), 1.78-1.75 (1H, m), 1.67-0.95 (10H, m),
0.88 (6H, s), 0.82 (3H, s)

【0030】応用例5 〇 ALB307の合成 ALB305の4.18g(12.2mmol)をメタノール165
mlに溶解し、過ヨウ素酸ナトリウム6.61g(30.9mm
ol)を加え室温で12時間攪拌した。反応液を減圧下溶
媒留去し、残渣にエーテルを加え不溶物を濾去し、濾液
を減圧下、溶媒留去した。得られた残渣をt-ブタノール
120mlと水30mlの混合溶媒に溶解し、リン酸二水素
ナトリウム二水和物3.23g(20.7mmol)及び亜塩素
酸ナトリウム8.29g(72.4mmol)を加え室温で15
時間攪拌した。氷冷下、反応液に1N塩酸200mlを加
え、クロロホルムで3回抽出した。有機層を合わせ無水
硫酸ナトリウムで乾燥後、減圧下溶媒留去した。得られ
た残渣をメタノール150mlに溶解し、ジシクロヘキシ
ルカルボジイミド4.54g(22.0mmol)を加え、室温
で12時間攪拌した。反応液を減圧下溶媒留去し、残渣
にn-ヘキサンを加え不溶物を濾去し、濾液を減圧下溶媒
留去した。得られた残渣をシリカゲルカラムクロマトグ
ラフィー(SiO2:400ml,酢酸エチル/ヘキサン=1
6/84)で精製し下記構造式で示される化合物(以下A
LB307という)1.25g(収率:35%)を白色固体とし
て得た。その1H-NMR(400MHz)スペクトルデータは以下の
とおりである。 (CDCl3,ppm):4.16(1H,d,J=16.1Hz),4.05(1H,d,J=16.1H
z),3.85(1H,dd,J=9.3,7.3Hz), 3.74(3H,s), 3.66(1H,d
d,J=9.3,3.4Hz), 2.50-2.36(3H,m), 2.09-1.23(8H,m),
0.97(3H,s), 0.91-0.88(1H,m), 0.85(3H,s), 0.72(3H,
s).
Application Example 5 Synthesis of ALB307 4.18 g (12.2 mmol) of ALB305 was added to methanol 165
of sodium periodate (6.61 g, 30.9 mm).
ol) and stirred at room temperature for 12 hours. The solvent was distilled off from the reaction solution under reduced pressure, ether was added to the residue, the insoluble matter was removed by filtration, and the filtrate was evaporated under reduced pressure. The obtained residue was dissolved in a mixed solvent of 120 ml of t-butanol and 30 ml of water, and 3.23 g (20.7 mmol) of sodium dihydrogen phosphate dihydrate and 8.29 g (72.4 mmol) of sodium chlorite were added. Plus 15 at room temperature
Stirred for hours. Under ice-cooling, 200 ml of 1N hydrochloric acid was added to the reaction solution, and the mixture was extracted three times with chloroform. The organic layers were combined, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was dissolved in methanol (150 ml), dicyclohexylcarbodiimide (4.54 g, 22.0 mmol) was added, and the mixture was stirred at room temperature for 12 hours. The solvent was distilled off from the reaction solution under reduced pressure, n-hexane was added to the residue, the insoluble matter was removed by filtration, and the filtrate was evaporated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (SiO 2 : 400 ml, ethyl acetate / hexane = 1).
6/84) and purified by a compound represented by the following structural formula (hereinafter A).
1.25 g (yield: 35%) of LB307 were obtained as a white solid. The 1 H-NMR (400 MHz) spectrum data is as follows. (CDCl 3 , ppm): 4.16 (1H, d, J = 16.1Hz), 4.05 (1H, d, J = 16.1H
z), 3.85 (1H, dd, J = 9.3, 7.3 Hz), 3.74 (3H, s), 3.66 (1H, d
d, J = 9.3,3.4Hz), 2.50-2.36 (3H, m), 2.09-1.23 (8H, m),
0.97 (3H, s), 0.91-0.88 (1H, m), 0.85 (3H, s), 0.72 (3H,
s).

【0031】[0031]

【化7】 Embedded image

【0032】応用例6 〇 ALB308の合成 ALB305の0.88g(2.57mmol)をメタノール35ml
に溶解し、過ヨウ素酸ナトリウム1.39g(6.50mmo
l)を加え室温で12時間攪拌した。反応液を減圧下溶媒
留去し、残さにエーテルに加え不溶物を濾去し、濾液を
減圧下溶媒留去した。得られた残渣をメタノール30ml
に溶解し、氷冷下水素化ホウ素ナトリウム494mg(1
3.1mmol)を加え、室温で15時間攪拌した。氷冷下、
反応液に飽和塩化アンモニウム水溶液を加えた後、クロ
ロホルムで3回抽出した。有機層を合わせ無水硫酸ナト
リウムで乾燥後、減圧下溶媒留去し、得られた残渣をシ
リカゲルカラムクロマトグラフィー(SiO2:100m
l,酢酸エチル/ヘキサン=32/68)で精製し下記構造
式で示される化合物(以下ALB308という)760mg(収
率:95%)を油状物質として得た。その1H-NMR(400MH
z)スペクトルデータは以下のとおりである。 (CDCl3,ppm): 4.04-3.82(4H,m), 3.72-3.59(2H,m), 3.5
6-3.46(4H,m), 2.65(1H,brs), 1.94-1.54(5H,m), 1.47-
1.33(4H,m), 1.26-1.08(2H,m), 0.98-0.95(1H,m), 0.90
(3H,s), 0.88(3H,s), 0.83(3H,s).
Application Example 6 Synthesis of ALB308 0.88 g (2.57 mmol) of ALB305 was added to 35 ml of methanol.
And dissolved in 1.39 g of sodium periodate (6.50 mmo).
l) was added and the mixture was stirred at room temperature for 12 hours. The solvent was distilled off from the reaction solution under reduced pressure, the residue was added to ether, and insolubles were removed by filtration. The filtrate was evaporated under reduced pressure. 30 ml of the obtained residue in methanol
And 494 mg of sodium borohydride (1
3.1 mmol) and stirred at room temperature for 15 hours. below freezing,
After adding a saturated aqueous solution of ammonium chloride to the reaction mixture, the mixture was extracted three times with chloroform. The organic layers were combined, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The resulting residue was subjected to silica gel column chromatography (SiO 2 : 100 m 2).
l, ethyl acetate / hexane = 32/68) to obtain 760 mg (yield: 95%) of a compound represented by the following structural formula (hereinafter referred to as ALB308) as an oily substance. Part 1 H-NMR (400MH
z) The spectrum data is as follows. (CDCl 3 , ppm): 4.04-3.82 (4H, m), 3.72-3.59 (2H, m), 3.5
6-3.46 (4H, m), 2.65 (1H, brs), 1.94-1.54 (5H, m), 1.47-
1.33 (4H, m), 1.26-1.08 (2H, m), 0.98-0.95 (1H, m), 0.90
(3H, s), 0.88 (3H, s), 0.83 (3H, s).

【0033】[0033]

【化8】 Embedded image

【0034】○ 化合物の特性測定 実施例2、応用例3〜6で合成された各化合物の抗真菌
活性及び感染治療試験の結果を表3、表4に示す。
測定 Measurement of compound properties Tables 3 and 4 show the results of the antifungal activity and infection treatment tests of the compounds synthesized in Example 2 and Application Examples 3 to 6, respectively.

【0035】[0035]

【表3】 [Table 3]

【0036】[0036]

【表4】 [Table 4]

【0037】実施例3 ○ ALB−320の合成 実施例1で合成したAT−2(1.85g:6.25mmol)
のジクロロメタン(20ml)溶液に、氷冷下撹拌しながら
クロロメチルメチルエーテル(715μl:9.38mmol)
及びジイソプロピルエチルアミン(1.74ml:9.99m
mol)を順次加えた。反応液を室温下8時間撹拌後、クロ
ロホルム(30ml)及び水(30ml)を加え生成物を抽出
し、抽出液は1N塩酸、飽和炭酸水素ナトリウム水溶液
及び飽和食塩水で順次洗浄した。無水硫酸マグネシウム
で乾燥後溶媒を留去し、残渣をシリカゲルカラムクロマ
トグラフィー[30g:2.0cmIDx20.5、溶出溶媒:
n-ヘキサンー酢酸エチル=100/0→60/40]によ
り精製して下記構造式で示される化合物(以下AT-6と
いう)621mgを無色飴状物質として得た。その1H-NMR
スペクトル(400MHz)は以下のとおりであった。 (CDCl3,ppm): 0.79(3H,s,Me-C10), 0.83(3H,s,Meβ-C
4), 0.87(3H,s,Meα-C4),1.23(3H,s,Me-C8), 2.06(1H,d
dd,J=12.2,3.4,2.9,H7), 3.37(3H,s,OCH2OCH3),3.45(1
H,ddd,J=9.8,9.8,4.4,H12), 3.72(1H,ddd,J=9.8,5.4,4.
4,H12'), 4.75(2H,s, OCH2OCH3)
Example 3 Synthesis of ALB-320 AT-2 synthesized in Example 1 (1.85 g: 6.25 mmol)
Chloromethyl methyl ether (715 μl: 9.38 mmol) was added to a dichloromethane (20 ml) solution while stirring under ice cooling.
And diisopropylethylamine (1.74 ml: 9.99 m)
mol) were added sequentially. After stirring the reaction solution at room temperature for 8 hours, chloroform (30 ml) and water (30 ml) were added to extract the product, and the extract was washed successively with 1N hydrochloric acid, a saturated aqueous solution of sodium hydrogen carbonate and a saturated saline solution. After drying over anhydrous magnesium sulfate, the solvent was distilled off, and the residue was subjected to silica gel column chromatography [30 g: 2.0 cm ID × 20.5, elution solvent:
n-hexane-ethyl acetate = 100/0 → 60/40] to obtain 621 mg of a compound represented by the following structural formula (hereinafter referred to as AT-6) as a colorless candy substance. Part 1 H-NMR
The spectrum (400 MHz) was as follows. (CDCl 3 , ppm): 0.79 (3H, s, Me-C10), 0.83 (3H, s, Meβ-C
4), 0.87 (3H, s, Meα-C4), 1.23 (3H, s, Me-C8), 2.06 (1H, d
dd, J = 12.2,3.4,2.9, H7), 3.37 (3H, s, OCH 2 OCH 3 ), 3.45 (1
H, ddd, J = 9.8,9.8,4.4, H12), 3.72 (1H, ddd, J = 9.8,5.4,4.
4, H12 '), 4.75 (2H, s, OCH 2 OCH 3 )

【0038】[0038]

【化9】 Embedded image

【0039】AT-6の10.0g(33.5mmol)をTHF
200mlに溶解し、氷冷、窒素雰囲気下60%水素化ナ
トリウム/流動パラフィン2.68g(67mmol)を加え、
室温で1時間攪拌した。氷冷下、反応液にヨウ化アリル
6.2ml(68mmol)を加え、室温で7時間攪拌した。氷
冷下、反応液に60%水素化ナトリウム/流動パラフィ
ン1.34g(34mmol)、ヨウ化アリル3.1ml(34mmo
l)を更に加え、室温で13時間攪拌した。反応液を氷冷
後、飽和塩化アンモニウム水溶液200mlを加え、酢酸
エチルで抽出した。有機層を飽和食塩水で3回洗浄し、
得られた有機層を無水硫酸ナトリウムで乾燥後、減圧下
溶媒留去した。得られた残渣をシリカゲルカラムクロマ
トグラフィー(SiO2:600ml,酢酸エチル/ヘキサン
=4/96)で精製し、8位にメチル基、メトキシメチル
オキシ基、9位にアリルオキシエチル基を有する下記構
造式で示されるヒドロナフタレン(以下ALB320とい
う)11.0g(収率:97%)を油状物質として得た。そ
1H-NMR(400MHz)スペクトルデータは以下のとおりであ
る。 (CDCl3,ppm): 5.91(1H,ddt,J=17.6,10.3,5.9Hz), 5.26
(1H,dt,J=17.6,1.5Hz),5.15(1H,dt,J=10.3,1.5Hz), 4.7
2(1H,d,J=7.3Hz), 4.63(1H,d,J=7.3Hz), 3.96(2H,dt,J=
5.9,1.5Hz), 3.51(1H,ddd,J=10.7,8.8,5.9Hz), 3.37(1
H,ddd,J=10.7,8.8,5.9Hz), 3.33(3H,s), 1.94(1H,dt,J=
12.2,2.9Hz), 1.77-1.09(11H,m), 1.20(3H,s), 0.92-0.
88(2H,m), 0.85(3H,s), 0.82(3H,s), 0.78(3H,s).
10.0 g (33.5 mmol) of AT-6 was added to THF
Dissolved in 200 ml and added 2.68 g (67 mmol) of 60% sodium hydride / liquid paraffin under ice cooling and nitrogen atmosphere.
Stirred at room temperature for 1 hour. Under ice-cooling, 6.2 ml (68 mmol) of allyl iodide was added to the reaction solution, and the mixture was stirred at room temperature for 7 hours. Under ice-cooling, 1.34 g (34 mmol) of 60% sodium hydride / liquid paraffin and 3.1 ml of allyl iodide (34 mmol) were added to the reaction mixture.
l) was further added and the mixture was stirred at room temperature for 13 hours. After cooling the reaction solution on ice, 200 ml of a saturated aqueous solution of ammonium chloride was added, and the mixture was extracted with ethyl acetate. The organic layer was washed three times with a saturated saline solution,
After the obtained organic layer was dried over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography (SiO 2 : 600 ml, ethyl acetate / hexane = 4/96), and the following structure having a methyl group, a methoxymethyloxy group at the 8-position, and an allyloxyethyl group at the 9-position 11.0 g (yield: 97%) of hydronaphthalene (hereinafter referred to as ALB320) represented by the formula was obtained as an oily substance. The 1 H-NMR (400 MHz) spectrum data is as follows. (CDCl 3 , ppm): 5.91 (1H, ddt, J = 17.6,10.3,5.9Hz), 5.26
(1H, dt, J = 17.6,1.5Hz), 5.15 (1H, dt, J = 10.3,1.5Hz), 4.7
2 (1H, d, J = 7.3Hz), 4.63 (1H, d, J = 7.3Hz), 3.96 (2H, dt, J =
5.9,1.5Hz), 3.51 (1H, ddd, J = 10.7,8.8,5.9Hz), 3.37 (1
H, ddd, J = 10.7,8.8,5.9Hz), 3.33 (3H, s), 1.94 (1H, dt, J =
12.2,2.9Hz), 1.77-1.09 (11H, m), 1.20 (3H, s), 0.92-0.
88 (2H, m), 0.85 (3H, s), 0.82 (3H, s), 0.78 (3H, s).

【0040】[0040]

【化10】 Embedded image

【0041】応用例7 〇 ALB321の合成 ALB320の5.56g(16.4mmol)を用い、ALB304
とほぼ同様の操作を行った。得られた残渣をシリカゲル
カラムクロマトグラフィー(SiO2:500ml,酢酸エ
チル/ヘキサン=16/84)で精製し下記構造式で示さ
れる化合物(以下ALB321という)4.79g(収率:83
%)を油状物質として得た。その1H-NMR(400MHz)スペク
トルデータは以下のとおりである。 (CDCl3,ppm): 4.72(1H,d,J=7.3Hz), 4.64(1H,d,J=7.3H
z), 3.70-3.66(1H,m), 3.60-3.53(1H,m), 3.48-3.38(2
H,m), 3.34(3H,s), 3.16-3.13(1H,m), 2.80(1H,t,J=4.9
Hz), 2.62-2.60(1H,m), 1.95(1H,dt,J=12.2,3.4Hz), 1.
77-1.10(11H,m), 1.21(3H,s), 0.92-0.87(2H,m), 0.86
(3H,s), 0.83(3H,s), 0.78(3H,s).
Application Example 7 Synthesis of ALB321 ALB304 was prepared using 5.56 g (16.4 mmol) of ALB320.
Almost the same operation was performed. The resulting residue was purified by silica gel column chromatography (SiO 2 : 500 ml, ethyl acetate / hexane = 16/84), and 4.79 g (yield: 83) of a compound represented by the following structural formula (hereinafter referred to as ALB321) was obtained.
%) As an oil. The 1 H-NMR (400 MHz) spectrum data is as follows. (CDCl 3 , ppm): 4.72 (1H, d, J = 7.3Hz), 4.64 (1H, d, J = 7.3H
z), 3.70-3.66 (1H, m), 3.60-3.53 (1H, m), 3.48-3.38 (2
H, m), 3.34 (3H, s), 3.16-3.13 (1H, m), 2.80 (1H, t, J = 4.9
Hz), 2.62-2.60 (1H, m), 1.95 (1H, dt, J = 12.2,3.4Hz), 1.
77-1.10 (11H, m), 1.21 (3H, s), 0.92-0.87 (2H, m), 0.86
(3H, s), 0.83 (3H, s), 0.78 (3H, s).

【0042】[0042]

【化11】 Embedded image

【0043】応用例8 〇 ALB322の合成 ALB321の4.22g(11.9mmol)を用い、ALB305
とほぼ同様の操作を行った。得られた残さをシリカゲル
カラムクロマトグラフィー(SiO2:500ml,酢酸エ
チル/ヘキサン=67/23〜0/100)で精製し、8位
にメチル基、メトキシメチルオキシ基、9位に(2,3-ジ
ヒドロキシプロピル)オキシエチル基を有するヒドロナ
フタレン(以下ALB322という)3.84g(収率:87
%)を油状物質として得た。その1H-NMR(400MHz)スペク
トルデータは以下のとおりである。 (CDCl3,ppm): 4.73(1H,d,J=7.3Hz), 4.65(1H,d,J=7.3H
z), 3.86-3.84(1H,m), 3.74-3.64(2H,m), 3.57-3.45(4
H,m), 3.34(3H,s), 1.97(1H,dt,J=12.2,3.4Hz), 1.74-
1.15(11H,m), 1.21(3H,s), 0.93-0.90(2H,m), 0.86(3H,
s), 0.83(3H,s), 0.79(3H,s).
Application Example 8 Synthesis of ALB322 Using 4.22 g (11.9 mmol) of ALB321, ALB305 was used.
Almost the same operation was performed. The resulting residue by silica gel column chromatography (SiO 2: 500 ml, ethyl acetate / hexane = 67/23 to 0/100) to give methyl group at the 8-position, methoxymethyl group, the 9-position (2,3 3.84 g of hydronaphthalene (hereinafter referred to as ALB322) having -dihydroxypropyl) oxyethyl group (yield: 87
%) As an oil. The 1 H-NMR (400 MHz) spectrum data is as follows. (CDCl 3 , ppm): 4.73 (1H, d, J = 7.3Hz), 4.65 (1H, d, J = 7.3H
z), 3.86-3.84 (1H, m), 3.74-3.64 (2H, m), 3.57-3.45 (4
H, m), 3.34 (3H, s), 1.97 (1H, dt, J = 12.2,3.4Hz), 1.74-
1.15 (11H, m), 1.21 (3H, s), 0.93-0.90 (2H, m), 0.86 (3H,
s), 0.83 (3H, s), 0.79 (3H, s).

【0044】応用例9 〇 ALB325の合成 ALB322の5.17g(7.17mmol)を用い、ALB307
とほぼ同様の操作を行った。得られた残渣をシリカゲル
カラムクロマトグラフィー(SiO2:400ml,酢酸エ
チル/ヘキサン=16/84)で精製し下記構造式で示さ
れる化合物(以下ALB325という)1.33g(収率:50
%)を白色固体として得た。その1H-NMR(400MHz)スペク
トルデータは以下のとおりである。 (CDCl3,ppm): 4.72(1H,d,J=7.8Hz), 4.64(1H,d,J=7.8H
z), 4.09(2H,s), 3.75(3H,s), 3.65-3.58(1H,m), 3.50-
3.44(1H,m), 3.34(3H,s), 1.96(1H,dt,J=12.2,3.4Hz),
1.82-1.10(11H,m), 1.21(3H,s), 0.90(2H,dd,J=12.2,2.
0Hz), 0.86(3H,s), 0.83(3H,s), 0.78(3H,s).
Application Example 9 Synthesis of ALB325 Using 5.17 g (7.17 mmol) of ALB322, ALB307 was used.
Almost the same operation was performed. The obtained residue was purified by silica gel column chromatography (SiO 2 : 400 ml, ethyl acetate / hexane = 16/84), and 1.33 g (yield: 50) of a compound represented by the following structural formula (hereinafter referred to as ALB325) was obtained.
%) As a white solid. The 1 H-NMR (400 MHz) spectrum data is as follows. (CDCl 3 , ppm): 4.72 (1H, d, J = 7.8Hz), 4.64 (1H, d, J = 7.8H
z), 4.09 (2H, s), 3.75 (3H, s), 3.65-3.58 (1H, m), 3.50-
3.44 (1H, m), 3.34 (3H, s), 1.96 (1H, dt, J = 12.2,3.4Hz),
1.82-1.10 (11H, m), 1.21 (3H, s), 0.90 (2H, dd, J = 12.2,2.
0Hz), 0.86 (3H, s), 0.83 (3H, s), 0.78 (3H, s).

【0045】[0045]

【化12】 Embedded image

【0046】応用例10 〇 ALB327の合成 ALB325の1.00g(2.70mmol)を窒素雰囲気下TH
F20mlに溶解し−78℃に冷却した後、2Mリチウム
ジイソプロピルアミドヘプタン/THF/エチルベンゼン
溶液1.49ml(2.98mmol)を5分かけて加え、−78
℃で1時間攪拌した。反応液にマレイン酸ジエチル0.
53ml(3.28mmol)を5分かけて加え、−78℃から
0℃まで6時間かけて昇温した。反応液に飽和塩化アン
モニウム水溶液20mlを加え、室温で一晩攪拌した。反
応液に酢酸エチルを加え、飽和食塩水で3回洗浄し、得
られた有機層を無水硫酸ナトリウムで乾燥後、減圧下溶
媒留去した。得られた残渣をシリカゲルカラムクロマト
グラフィー(SiO2:100ml,酢酸エチル/n-ヘキサン
=16/84〜32/68)で精製し黄色油状物質803m
g(収率:55%)を得た。該黄色油状物質700mg(1.
29mmol)をエタノール7mlに溶解し、6N水酸化ナトリ
ウム水溶液7mlを加えて48時間攪拌した。氷冷下反応
液へ2N塩酸30mlを加えた後、クロロホルムで3回抽
出した。得られた有機層を無水硫酸ナトリウムで乾燥
後、減圧下溶媒留去し、得られた残渣をシリカゲルカラ
ムクロマトグラフィー(SiO2:50ml,メタノール/ク
ロロホルム=16/84〜24/76)で精製し、8位に
メチル基、メトキシメチルオキシ基、9位に(1,2,3-ト
リカルボキシプロピル)オキシエチル基を有する下記構
造式で示されるヒドロナフタレン(以下ALB327とい
う)253mg(収率:42%)を白色粉末として得た。そ
1H-NMR(400MHz)スペクトルデータは以下のとおりであ
る。 (CDCl3,ppm): 4.74(1H,d,J=7.8Hz), 4.66(1H,d,J=7.8H
z), 3.67-3.48(3H,m), 3.34(3H,s), 2.00(1H,dt,J=12.
2,3.4Hz), 1.82-1.11(14H,m), 1.22(3H,s), 0.91(2H,d
d,J=12.2,2.0Hz), 0.87(3H,s), 0.84(3H,s), 0.79(3H,
s).
Application Example 10 Synthesis of ALB327 1.00 g (2.70 mmol) of ALB325 was added to TH under a nitrogen atmosphere.
After dissolving in 20 ml of F and cooling to −78 ° C., 1.49 ml (2.98 mmol) of a 2M lithium diisopropylamidoheptane / THF / ethylbenzene solution was added over 5 minutes, and −78 ° C.
Stirred at C for 1 hour. Diethyl maleate was added to the reaction mixture at 0.
53 ml (3.28 mmol) was added over 5 minutes, and the temperature was raised from -78 ° C to 0 ° C over 6 hours. 20 ml of a saturated aqueous solution of ammonium chloride was added to the reaction solution, and the mixture was stirred at room temperature overnight. Ethyl acetate was added to the reaction solution, and the mixture was washed three times with a saturated saline solution. The obtained organic layer was dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography (SiO 2 : 100 ml, ethyl acetate / n-hexane = 16/84 to 32/68) to obtain a yellow oily substance (803 m)
g (yield: 55%) was obtained. 700 mg of the yellow oil (1.
29 mmol) was dissolved in 7 ml of ethanol, 7 ml of a 6N aqueous sodium hydroxide solution was added, and the mixture was stirred for 48 hours. After adding 30 ml of 2N hydrochloric acid to the reaction mixture under ice cooling, the mixture was extracted three times with chloroform. After the obtained organic layer was dried over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure, and the obtained residue was purified by silica gel column chromatography (SiO 2 : 50 ml, methanol / chloroform = 16/84 to 24/76). 253 mg (yield: 42%) of a hydronaphthalene represented by the following structural formula having a methyl group, a methoxymethyloxy group at the 8-position and a (1,2,3-tricarboxypropyl) oxyethyl group at the 9-position. ) Was obtained as a white powder. The 1 H-NMR (400 MHz) spectrum data is as follows. (CDCl 3 , ppm): 4.74 (1H, d, J = 7.8Hz), 4.66 (1H, d, J = 7.8H
z), 3.67-3.48 (3H, m), 3.34 (3H, s), 2.00 (1H, dt, J = 12.
2,3.4Hz), 1.82-1.11 (14H, m), 1.22 (3H, s), 0.91 (2H, d
d, J = 12.2,2.0Hz), 0.87 (3H, s), 0.84 (3H, s), 0.79 (3H,
s).

【0047】[0047]

【化13】 Embedded image

【0048】応用例11 〇 ALB328の合成 ALB322の644mg(1.73mmol)を用い、ALB308
とほぼ同様の操作を行った。得られた残渣をシリカゲル
カラムクロマトグラフィー(SiO2:100ml,酢酸エ
チル/ヘキサン=32/68)で精製し、8位にメチル
基、メトキシメチルオキシ基、9位に(2-ヒドロキシエ
チル)オキシエチル基を有するヒドロナフタレン(以下A
LB328という)426mg(収率:72%)を油状物質とし
て得た。その1H-NMR(400MHz)スペクトルデータは以下の
とおりである。 (CDCl3,ppm): 4.73(1H,d,J=7.3Hz), 4.65(1H,d,J=7.3H
z), 3.72-3.71(2H,m), 3.58-3.42(4H,m), 3.34(3H,s),
2.21(1H,brs), 1.96(1H,dt,J=12.2,3.4Hz), 1.78-1.11
(11H,m), 1.21(3H,s), 0.93-0.89(2H,m), 0.86(3H,s),
0.83(3H,s), 0.79(3H,s).
Application Example 11 Synthesis of ALB328 Using 644 mg (1.73 mmol) of ALB322, ALB308 was used.
Almost the same operation was performed. The obtained residue was purified by silica gel column chromatography (SiO 2 : 100 ml, ethyl acetate / hexane = 32/68), and a methyl group and a methoxymethyloxy group were placed at the 8-position, and a (2-hydroxyethyl) oxyethyl group was placed at the 9-position. (Hereinafter A)
426 mg (Yield: 72%) of LB328) were obtained as an oil. The 1 H-NMR (400 MHz) spectrum data is as follows. (CDCl 3 , ppm): 4.73 (1H, d, J = 7.3Hz), 4.65 (1H, d, J = 7.3H
z), 3.72-3.71 (2H, m), 3.58-3.42 (4H, m), 3.34 (3H, s),
2.21 (1H, brs), 1.96 (1H, dt, J = 12.2,3.4Hz), 1.78-1.11
(11H, m), 1.21 (3H, s), 0.93-0.89 (2H, m), 0.86 (3H, s),
0.83 (3H, s), 0.79 (3H, s).

【0049】応用例12 〇 ALB329の合成 ALB321の250mg(0.705mmol)及び1,2,4-トリア
ゾール73mg(1.06mmol)をN,N-ジメチルホルムアミ
ド5mlに溶解し、カリウムt-ブトキシド95mg(0.84
7mmol)を加え、60℃で6時間攪拌した。反応液を氷
冷後、飽和塩化アンモニウム水溶液を加え、酢酸エチル
で抽出した。有機層を飽和食塩水で3回洗浄し、得られ
た有機層を無水硫酸ナトリウムで乾燥後、減圧下溶媒留
去した。得られた残渣をシリカゲルカラムクロマトグラ
フィー(SiO2:50ml,メタノール/クロロホルム=1
/99〜2/98)で精製し下記構造式で示される化合物
(以下ALB329という)205mg(収率:69%)を白色
粉末として得た。その1H-NMR(400MHz)スペクトルデータ
は以下のとおりである。 (CDCl3,ppm): 8.16(1H,s), 7.95(1H,s), 4.71(1H,d,J=
7.3Hz), 4.64(1H,d,J=7.3Hz), 4.35(1H,dd,J=13.7,3.9H
z), 4.25(1H,dd,J=13.7,6.8Hz), 4.19-4.09(1H,m), 3.5
3-3.34(4H,m), 3.33(3H,s), 3.21(1H,d,J=4.9Hz), 1.97
(1H,dt,J=12.2,3.4Hz), 1.78-1.11(11H,m), 1.21(3H,
s), 0.92-0.88(2H,m), 0.86(3H,s), 0.83(3H,s), 0.79
(3H,s).
Application Example 12 Synthesis of ALB329 250 mg (0.705 mmol) of ALB321 and 73 mg (1.06 mmol) of 1,2,4-triazole were dissolved in 5 ml of N, N-dimethylformamide, and 95 mg of potassium t-butoxide (95 mg) was dissolved. 0.84
7 mmol) and stirred at 60 ° C. for 6 hours. After cooling the reaction solution with ice, a saturated aqueous solution of ammonium chloride was added, and the mixture was extracted with ethyl acetate. The organic layer was washed three times with a saturated saline solution, and the obtained organic layer was dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was subjected to silica gel column chromatography (SiO 2 : 50 ml, methanol / chloroform = 1).
/ 99-2/98) and purified by the following structural formula
205 mg (yield: 69%) (hereinafter referred to as ALB329) was obtained as a white powder. The 1 H-NMR (400 MHz) spectrum data is as follows. (CDCl 3 , ppm): 8.16 (1H, s), 7.95 (1H, s), 4.71 (1H, d, J =
7.3Hz), 4.64 (1H, d, J = 7.3Hz), 4.35 (1H, dd, J = 13.7,3.9H
z), 4.25 (1H, dd, J = 13.7,6.8Hz), 4.19-4.09 (1H, m), 3.5
3-3.34 (4H, m), 3.33 (3H, s), 3.21 (1H, d, J = 4.9Hz), 1.97
(1H, dt, J = 12.2,3.4Hz), 1.78-1.11 (11H, m), 1.21 (3H,
s), 0.92-0.88 (2H, m), 0.86 (3H, s), 0.83 (3H, s), 0.79
(3H, s).

【0050】[0050]

【化14】 Embedded image

【0051】応用例13 〇 ALB330の合成 ALB321の250mg(0.705mmol)、1-(3-アミノプ
ロピル)イミダゾール0.1ml(0.838mmol)及び過塩
素酸リチウム150mg(1.41mmol)をアセトニトリル
5mlに懸濁し、50℃で4時間攪拌した。反応液を室温
まで冷却した後、飽和炭酸水素ナトリウム水溶液を加
え、クロロホルムで抽出した。有機層を飽和炭酸水素ナ
トリウム水溶液で2回、飽和食塩水で1回洗浄し、得ら
れた有機層を無水硫酸ナトリウムで乾燥後、減圧下溶媒
留去した。得られた残渣をシリカゲルカラムクロマトグ
ラフィー(SiO2:50ml,メタノール/クロロホルム=
8/92〜16/84)で精製し下記構造式で示される化
合物(以下ALB330という)216mg(収率:64%)を
油状物質として得た。その1H-NMR(400MHz)スペクトルデ
ータは以下のとおりである。 (CDCl3,ppm): 7.51(1H,s), 7.02(1H,s), 6.94(1H,s),
4.72(1H,d,J=7.3Hz), 4.64(1H,d,J=7.3Hz), 3.92-3.81
(1H,m), 3.52-3.39(4H,m), 3.34(3H,s), 2.70-2.61(4H,
m), 2.18(3H,s), 2.00-1.94(3H,m), 1.76-1.11(11H,m),
1.21(3H,s), 0.91-0.89(2H,m), 0.86(3H,s), 0.83(3H,
s), 0.78(3H,s).
Application Example 13 Synthesis of ALB330 250 mg (0.705 mmol) of ALB321, 0.1 ml (0.838 mmol) of 1- (3-aminopropyl) imidazole and 150 mg (1.41 mmol) of lithium perchlorate were added to 5 ml of acetonitrile. And stirred at 50 ° C. for 4 hours. After the reaction solution was cooled to room temperature, a saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted with chloroform. The organic layer was washed twice with a saturated aqueous solution of sodium hydrogen carbonate and once with a saturated saline solution. The obtained organic layer was dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was subjected to silica gel column chromatography (SiO 2 : 50 ml, methanol / chloroform =
8/92 to 16/84) to give 216 mg (yield: 64%) of a compound represented by the following structural formula (hereinafter referred to as ALB330) as an oily substance. The 1 H-NMR (400 MHz) spectrum data is as follows. (CDCl 3 , ppm): 7.51 (1H, s), 7.02 (1H, s), 6.94 (1H, s),
4.72 (1H, d, J = 7.3Hz), 4.64 (1H, d, J = 7.3Hz), 3.92-3.81
(1H, m), 3.52-3.39 (4H, m), 3.34 (3H, s), 2.70-2.61 (4H, m
m), 2.18 (3H, s), 2.00-1.94 (3H, m), 1.76-1.11 (11H, m),
1.21 (3H, s), 0.91-0.89 (2H, m), 0.86 (3H, s), 0.83 (3H,
s), 0.78 (3H, s).

【0052】[0052]

【化15】 Embedded image

【0053】応用例14 〇 ALB331の合成 ALB321の250mg(0.705mmol)及び4-(3-アミノ
プロピル)モルホリン0.12ml(0.821mmol)を用
い、ALB330とほぼ同様の操作を行った。得られた残
渣をシリカゲルカラムクロマトグラフィー(SiO2:5
0ml,メタノール/クロロホルム=4/96〜16/84)
で精製し下記構造式で示される化合物(以下ALB331と
いう)283mg(収率:80%)を薄黄色粉末として得
た。その1H-NMR(400MHz)スペクトルデータは以下のとお
りである。 (CDCl3,ppm): 4.72(1H,d,J=7.3Hz), 4.64(1H,d,J=7.3H
z), 4.28-4.18(1H,m), 3.78-3.75(4H,m), 3.55-3.42(4
H,m), 3.34(3H,s), 3.10-2.93(4H,m), 2.70-2.47(8H,
m), 1.97-1.11(12H,m), 1.20(3H,s), 0.92-0.89(2H,m),
0.87(3H,s), 0.83(3H,s), 0.79(3H,s).
Application Example 14 Synthesis of ALB331 Using 250 mg (0.705 mmol) of ALB321 and 0.12 ml (0.821 mmol) of 4- (3-aminopropyl) morpholine, almost the same operation as in ALB330 was performed. The obtained residue is subjected to silica gel column chromatography (SiO 2 : 5).
0 ml, methanol / chloroform = 4/96 to 16/84)
And 283 mg (yield: 80%) of a compound represented by the following structural formula (hereinafter referred to as ALB331) was obtained as a pale yellow powder. The 1 H-NMR (400 MHz) spectrum data is as follows. (CDCl 3 , ppm): 4.72 (1H, d, J = 7.3Hz), 4.64 (1H, d, J = 7.3H
z), 4.28-4.18 (1H, m), 3.78-3.75 (4H, m), 3.55-3.42 (4
H, m), 3.34 (3H, s), 3.10-2.93 (4H, m), 2.70-2.47 (8H,
m), 1.97-1.11 (12H, m), 1.20 (3H, s), 0.92-0.89 (2H, m),
0.87 (3H, s), 0.83 (3H, s), 0.79 (3H, s).

【0054】[0054]

【化16】 Embedded image

【0055】応用例15 〇 ALB332の合成 ALB321 の250mg(0.705mmol)及びモルホリン
0.1ml(1.141mmol)を用い、ALB330とほぼ同様
の操作を行った。得られた残渣をシリカゲルカラムクロ
マトグラフィー(SiO2:50ml,メタノール/クロロホ
ルム=1/99〜2/98)で精製し下記構造式で示され
る化合物(以下ALB332という)278mg(収率:89
%)を油状物質として得た。その1H-NMR(400MHz)スペク
トルデータは以下のとおりである。 (CDCl3,ppm): 4.72(1H,d,J=7.3Hz), 4.64(1H,d,J=7.3H
z), 3.92-3.87(1H,m), 3.75-3.67(4H,m), 3.56-3.38(4
H,m), 3.34(3H,s), 2.65-2.60(2H,m), 2.49-2.37(4H,
m), 1.95(1H,dt,J=12.2,3.4Hz), 1.78-1.09(11H,m), 1.
21(3H,s), 0.90(2H,dd,J=12.2,2.4Hz), 0.86(3H,s), 0.
82(3H,s), 0.78(3H,s).
Application Example 15 Synthesis of ALB332 Using 250 mg (0.705 mmol) of ALB321 and 0.1 ml (1.141 mmol) of morpholine, almost the same operation as in ALB330 was performed. The obtained residue was purified by silica gel column chromatography (SiO 2 : 50 ml, methanol / chloroform = 1/99 to 2/98), and 278 mg of a compound represented by the following structural formula (hereinafter referred to as ALB332) (yield: 89)
%) As an oil. The 1 H-NMR (400 MHz) spectrum data is as follows. (CDCl 3 , ppm): 4.72 (1H, d, J = 7.3Hz), 4.64 (1H, d, J = 7.3H
z), 3.92-3.87 (1H, m), 3.75-3.67 (4H, m), 3.56-3.38 (4
H, m), 3.34 (3H, s), 2.65-2.60 (2H, m), 2.49-2.37 (4H,
m), 1.95 (1H, dt, J = 12.2,3.4Hz), 1.78-1.09 (11H, m), 1.
21 (3H, s), 0.90 (2H, dd, J = 12.2,2.4Hz), 0.86 (3H, s), 0.
82 (3H, s), 0.78 (3H, s).

【0056】[0056]

【化17】 Embedded image

【0057】応用例16 〇 ALB333の合成 ALB321の250mg(0.705mmol)及びピペリジン
0.1ml(1.01mmol)を用い、ALB330とほぼ同様の
操作を行った。得られた残渣をシリカゲルカラムクロマ
トグラフィー(SiO2:50ml,メタノール/クロロホル
ム=2/98〜4/96)で精製し下記構造式で示される
化合物(以下ALB333という)273mg(収率:88%)
を油状物質として得た。その1H-NMR(400MHz)スペクトル
データは以下のとおりである。 (CDCl3,ppm): 4.72(1H,d,J=7.3Hz), 4.64(1H,d,J=7.3H
z), 3.91-3.87(1H,m), 3.56-3.52(1H,m), 3.50-3.37(3
H,m), 3.34(3H,s), 2.63-2.60(2H,m), 2.41-2.38(4H,
m), 1.95(1H,dt,J=12.2,3.4Hz), 1.78-1.08(17H,m), 1.
20(3H,s), 0.90(2H,dd,J=12.2,2.4Hz), 0.86(3H,s), 0.
82(3H,s), 0.78(3H,s)
Application Example 16 Synthesis of ALB333 Using 250 mg (0.705 mmol) of ALB321 and 0.1 ml (1.01 mmol) of piperidine, the same operation as in ALB330 was performed. The obtained residue was purified by silica gel column chromatography (SiO 2 : 50 ml, methanol / chloroform = 2/98 to 4/96) and 273 mg (yield: 88%) of a compound represented by the following structural formula (hereinafter referred to as ALB333).
Was obtained as an oil. The 1 H-NMR (400 MHz) spectrum data is as follows. (CDCl 3 , ppm): 4.72 (1H, d, J = 7.3Hz), 4.64 (1H, d, J = 7.3H
z), 3.91-3.87 (1H, m), 3.56-3.52 (1H, m), 3.50-3.37 (3
H, m), 3.34 (3H, s), 2.63-2.60 (2H, m), 2.41-2.38 (4H,
m), 1.95 (1H, dt, J = 12.2,3.4Hz), 1.78-1.08 (17H, m), 1.
20 (3H, s), 0.90 (2H, dd, J = 12.2,2.4Hz), 0.86 (3H, s), 0.
82 (3H, s), 0.78 (3H, s)

【0058】[0058]

【化18】 Embedded image

【0059】応用例17 〇 ALB334の合成 ALB321の250mg(0.705mmol)及びN-メチルピペ
ラジン0.1ml(0.90mmol)を用い、ALB330とほぼ
同様の操作を行った。得られた残渣をシリカゲルカラム
クロマトグラフィー(SiO2:60ml,メタノール/クロ
ロホルム=4/96〜16/84)で精製し下記構造式で
示される化合物(以下ALB334という)248mg(収率:
77%)を油状物質として得た。その1H-NMR(400MHz)ス
ペクトルデータは以下のとおりである。 (CDCl3,ppm): 4.72(1H,d,J=7.3Hz), 4.64(1H,d,J=7.3H
z), 3.89-3.86(1H,m), 3.56-3.38(4H,m), 3.33(3H,s),
2.67-2.36(10H,m), 2.29(3H,s), 1.95(1H,dt,J=12.2,3.
4Hz), 1.78-1.09(11H,m), 1.20(3H,s), 0.90(2H,dd,J=1
2.2,2.4Hz), 0.86(3H,s), 0.82(3H,s), 0.78(3H,s)
Application Example 17 Synthesis of ALB 334 The same operation as ALB 330 was carried out using 250 mg (0.705 mmol) of ALB 321 and 0.1 ml (0.90 mmol) of N-methylpiperazine. The obtained residue was purified by silica gel column chromatography (SiO 2 : 60 ml, methanol / chloroform = 4/96 to 16/84), and 248 mg of a compound represented by the following structural formula (hereinafter referred to as ALB334) (yield:
77%) as an oil. The 1 H-NMR (400 MHz) spectrum data is as follows. (CDCl 3 , ppm): 4.72 (1H, d, J = 7.3Hz), 4.64 (1H, d, J = 7.3H
z), 3.89-3.86 (1H, m), 3.56-3.38 (4H, m), 3.33 (3H, s),
2.67-2.36 (10H, m), 2.29 (3H, s), 1.95 (1H, dt, J = 12.2,3.
4Hz), 1.78-1.09 (11H, m), 1.20 (3H, s), 0.90 (2H, dd, J = 1
2.2,2.4Hz), 0.86 (3H, s), 0.82 (3H, s), 0.78 (3H, s)

【0060】[0060]

【化19】 Embedded image

【0061】応用例18 〇 ALB335の合成 ALB321の250mg(0.705mmol)及び1-(2-ヒドロ
キシエチル)ピペラジン0.1ml(0.82mmol)を用い、
ALB330とほぼ同様の操作を行った。得られた残渣を
シリカゲルカラムクロマトグラフィー(SiO2:60m
l,メタノール/クロロホルム=4/96〜16/84)で
精製し下記構造式で示される化合物(以下ALB335とい
う)262mg(収率:77%)を油状物質として得た。そ
1H-NMR(400MHz)スペクトルデータは以下のとおりであ
る。 (CDCl3,ppm): 4.72(1H,d,J=7.3Hz), 4.64(1H,d,J=7.3H
z), 3.90-3.85(1H,m), 3.61(2H,t,J=5.4Hz), 3.56-3.38
(4H,m), 3.34(3H,s), 2.66-2.36(10H,m), 2.55(2H,t,J=
5.4Hz), 1.95(1H,dt,J=12.2,3.4Hz), 1.78-1.09(11H,
m), 1.21(3H,s), 0.90(2H,dd,J=12.2,2.4Hz), 0.86(3H,
s), 0.82(3H,s), 0.78(3H,s)
Application Example 18 Synthesis of ALB335 Using 250 mg (0.705 mmol) of ALB321 and 0.1 ml (0.82 mmol) of 1- (2-hydroxyethyl) piperazine,
Almost the same operation as in ALB330 was performed. The obtained residue is subjected to silica gel column chromatography (SiO 2 : 60 m2).
l, methanol / chloroform = 4/96 to 16/84) to obtain 262 mg (yield: 77%) of a compound represented by the following structural formula (hereinafter referred to as ALB335) as an oily substance. The 1 H-NMR (400 MHz) spectrum data is as follows. (CDCl 3 , ppm): 4.72 (1H, d, J = 7.3Hz), 4.64 (1H, d, J = 7.3H
z), 3.90-3.85 (1H, m), 3.61 (2H, t, J = 5.4Hz), 3.56-3.38
(4H, m), 3.34 (3H, s), 2.66-2.36 (10H, m), 2.55 (2H, t, J =
5.4Hz), 1.95 (1H, dt, J = 12.2,3.4Hz), 1.78-1.09 (11H,
m), 1.21 (3H, s), 0.90 (2H, dd, J = 12.2,2.4Hz), 0.86 (3H,
s), 0.82 (3H, s), 0.78 (3H, s)

【0062】[0062]

【化20】 Embedded image

【0063】応用例19 〇 ALB336の合成 ALB329の177mg(0.418mmol)をTHF0.5ml
と80%酢酸水溶液3mlの混合溶媒に溶解し、2N塩酸
0.2mlを加え、80℃で5時間攪拌した。反応液を減
圧下溶媒留去し、得られた残渣をクロロホルムに溶解
し、飽和炭酸水素ナトリウム水溶液で3回、飽和食塩水
で1回洗浄した。有機層を無水硫酸ナトリウムで乾燥
後、減圧下溶媒留去し、得られた残渣をシリカゲルカラ
ムクロマトグラフィー(SiO2:30ml,メタノール/ク
ロロホルム=1/99〜2/98)で精製し下記構造式で
示される化合物(以下ALB336という)を油状物質とし
て116mg(収率:73%)を油状物質として得た。その
1H-NMR(400MHz)スペクトルデータは以下のとおりであ
る。 (CDCl3,ppm): 8.14(1H,s), 7.94(1H,s), 4.36(1H,dd,J=
13.7,3.9Hz), 4.26(1H,dd,J=13.7,6.8Hz), 4.19-4.13(1
H,m), 3.47-3.34(4H,m), 3.19(1H,brs), 2.40-2.33(1H,
m), 2.26-2.19(1H,m), 2.03-0.90(11H,m), 1.59(3H,s),
0.94(6H,s), 0.88(3H,s)
Application Example 19 Synthesis of ALB336 177 mg (0.418 mmol) of ALB329 was added to 0.5 ml of THF.
And a 80% aqueous acetic acid solution (3 ml), dissolved in 2N hydrochloric acid (0.2 ml), and stirred at 80 ° C. for 5 hours. The solvent was distilled off from the reaction solution under reduced pressure, and the obtained residue was dissolved in chloroform, and washed three times with a saturated aqueous solution of sodium hydrogen carbonate and once with a saturated saline solution. After the organic layer was dried over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure, and the obtained residue was purified by silica gel column chromatography (SiO 2 : 30 ml, methanol / chloroform = 1/99 to 2/98) to give the following structural formula (Hereinafter referred to as ALB336) was obtained as an oily substance to obtain 116 mg (yield: 73%) as an oily substance. That
The 1 H-NMR (400 MHz) spectrum data is as follows. (CDCl 3 , ppm): 8.14 (1H, s), 7.94 (1H, s), 4.36 (1H, dd, J =
13.7,3.9Hz), 4.26 (1H, dd, J = 13.7,6.8Hz), 4.19-4.13 (1
H, m), 3.47-3.34 (4H, m), 3.19 (1H, brs), 2.40-2.33 (1H,
m), 2.26-2.19 (1H, m), 2.03-0.90 (11H, m), 1.59 (3H, s),
0.94 (6H, s), 0.88 (3H, s)

【0064】[0064]

【化21】 Embedded image

【0065】応用例19〜20 〇 ALB337及びALB338の合成 ALB321の500mg(1.41mmol)及びピペラジン73
mg(0.847mmol)を用い、ALB330とほぼ同様の操作
を行った。得られた残渣をシリカゲルカラムクロマトグ
ラフィー(SiO2:100ml,メタノール/クロロホルム
=2/98〜4/96、16/84〜24/76)で精製し
下記構造式で示される化合物(化83、以下ALB337と
いう)330mg(収率:59%)、下記構造式で示される
化合物(化84、以下ALB338という)330mg(収率:
29%)をそれぞれ油状物質として得た。その1H-NMR(40
0MHz)スペクトルデータは以下のとおりである。 ALB337 (CDCl3,ppm): 4.72(2H,d,J=7.3Hz), 4.64(2H,d,J=7.3H
z), 3.89-3.85(2H,m), 3.56-3.35(8H,m), 3.33(6H,s),
2.66-2.36(14H,m), 1.95(2H,dt,J=12.2,3.4Hz),1.78-1.
10(22H,m), 1.20(6H,s), 0.90(4H,dd,J=12.2,2.4Hz),
0.86(6H,s), 0.82(6H,s), 0.78(6H,s). ALB338 (CDCl3,ppm): 4.72(1H,d,J=7.3Hz), 4.64(1H,d,J=7.3H
z), 3.92-3.87(1H,m), 3.58-3.37(4H,m), 3.33(3H,s),
3.00-2.96(4H,m), 2.71-2.68(2H,m), 2.63-2.39(6H,m),
1.95(1H,dt,J=12.2,2.9Hz), 1.78-1.09(11H,m), 1.20
(3H,s), 0.90(2H,dd,J=12.2,1.5Hz), 0.86(3H,s), 0.82
(3H,s), 0.78(3H,s).
Application Examples 19 to 20 Synthesis of ALB337 and ALB338 500 mg (1.41 mmol) of ALB321 and piperazine 73
The same operation as in ALB330 was performed using mg (0.847 mmol). The obtained residue was purified by silica gel column chromatography (SiO 2 : 100 ml, methanol / chloroform = 2 / 98-4 / 96, 16 / 84-24 / 76) to give a compound represented by the following structural formula (Chemical Formula 83, hereinafter). 330 mg (yield: 59%) of ALB337, 330 mg (yield: ALB338) of a compound represented by the following structural formula
29%) were each obtained as an oil. Its 1 H-NMR (40
0 MHz) spectrum data is as follows. ALB337 (CDCl 3 , ppm): 4.72 (2H, d, J = 7.3Hz), 4.64 (2H, d, J = 7.3H
z), 3.89-3.85 (2H, m), 3.56-3.35 (8H, m), 3.33 (6H, s),
2.66-2.36 (14H, m), 1.95 (2H, dt, J = 12.2,3.4Hz), 1.78-1.
10 (22H, m), 1.20 (6H, s), 0.90 (4H, dd, J = 12.2,2.4Hz),
0.86 (6H, s), 0.82 (6H, s), 0.78 (6H, s) .ALB338 (CDCl 3 , ppm): 4.72 (1H, d, J = 7.3Hz), 4.64 (1H, d, J = 7.3 H
z), 3.92-3.87 (1H, m), 3.58-3.37 (4H, m), 3.33 (3H, s),
3.00-2.96 (4H, m), 2.71-2.68 (2H, m), 2.63-2.39 (6H, m),
1.95 (1H, dt, J = 12.2,2.9Hz), 1.78-1.09 (11H, m), 1.20
(3H, s), 0.90 (2H, dd, J = 12.2,1.5Hz), 0.86 (3H, s), 0.82
(3H, s), 0.78 (3H, s).

【0066】[0066]

【化22】 Embedded image

【0067】[0067]

【化23】 Embedded image

【0068】応用例21 〇 ALB339の合成 ALB321の250mg(0.705mmol)及びアジ化ナトリ
ウム69mg(1.06mmol)を用い、ALB330とほぼ同様
の操作を行った。得られた残渣をシリカゲルカラムクロ
マトグラフィー(SiO2:50ml,酢酸エチル/n-ヘキサ
ン;=16/84)で精製し、8位にメチル基、メトキシ
メチルオキシ基、9位に3-アジド-2-ヒドロキシプロピ
ルオキシエチル基を有するヒドロナフタレン(以下AL
B339という)209mg(収率:75%)を油状物質として
得た。その1H-NMR(400MHz)スペクトルデータは以下のと
おりである。 (CDCl3,ppm): 4.72(1H,d,J=7.3Hz), 4.65(1H,d,J=7.3H
z), 3.95-3.91(1H,m), 3.57-3.32(6H,m), 3.34(3H,s),
2.69(1H,d,J=4.4Hz), 1.97(1H,dt,J=12.7,2.9Hz), 1.78
-1.10(11H,m), 1.21(3H,s), 0.91(2H,d,J=11.7Hz), 0.8
6(3H,s), 0.83(3H,s), 0.79(3H,s).
Application Example 21 Synthesis of ALB 339 The same operation as ALB 330 was carried out using 250 mg (0.705 mmol) of ALB 321 and 69 mg (1.06 mmol) of sodium azide. The obtained residue was purified by silica gel column chromatography (SiO 2 : 50 ml, ethyl acetate / n-hexane; = 16/84), and a methyl group and a methoxymethyloxy group were placed at the 8-position, and 3-azido-2 was placed at the 9-position. -Hydroxynaphthalene having a hydroxypropyloxyethyl group (hereinafter referred to as AL
209 mg (yield: 75%) of B339 were obtained as an oil. The 1 H-NMR (400 MHz) spectrum data is as follows. (CDCl 3 , ppm): 4.72 (1H, d, J = 7.3Hz), 4.65 (1H, d, J = 7.3H
z), 3.95-3.91 (1H, m), 3.57-3.32 (6H, m), 3.34 (3H, s),
2.69 (1H, d, J = 4.4Hz), 1.97 (1H, dt, J = 12.7,2.9Hz), 1.78
-1.10 (11H, m), 1.21 (3H, s), 0.91 (2H, d, J = 11.7Hz), 0.8
6 (3H, s), 0.83 (3H, s), 0.79 (3H, s).

【0069】応用例22 〇 ALB340の合成 ALB321の250mg(0.705mmol)及びトリス(ヒド
ロキシメチル)アミノメタン128mg(1.06mmol)を用
い、ALB330とほぼ同様の操作を行った。得られた残
渣をシリカゲルカラムクロマトグラフィー(SiO2:50
ml,メタノール/クロロホルム=16/84〜28/72)
で精製し、8位にメチル基、メトキシメチルオキシ基、
9位に3-(トリス(ヒドロキシメチル)メチル)アミノ-2-
ヒドロキシプロピルオキシエチル基を有するヒドロナフ
タレン(以下ALB340という)189mg(収率:56%)
を油状物質として得た。その1H-NMR(400MHz)スペクトル
データは以下のとおりである。 (CDCl3,ppm): 4.72(1H,d,J=7.3Hz), 4.64(1H,d,J=7.3H
z), 3.95-3.91(1H,m), 3.64-3.12(9H,m), 3.60(6H,s),
3.34(3H,s), 2.86-2.83(1H,m), 2.72-2.63(1H,m), 1.95
(1H,d,J=12.7Hz), 1.78-1.12(11H,m), 1.20(3H,s), 0.9
0(2H,d,J=12.2Hz), 0.86(3H,s), 0.83(3H,s), 0.79(3H,
s).
Application Example 22 Synthesis of ALB340 Using 250 mg (0.705 mmol) of ALB321 and 128 mg (1.06 mmol) of tris (hydroxymethyl) aminomethane, almost the same operation as in ALB330 was performed. The obtained residue is subjected to silica gel column chromatography (SiO 2 : 50).
ml, methanol / chloroform = 16 / 84-28 / 72)
And a methyl group, a methoxymethyloxy group at the 8-position,
3- (tris (hydroxymethyl) methyl) amino-2-position at position 9
189 mg of hydronaphthalene having a hydroxypropyloxyethyl group (hereinafter referred to as ALB340) (yield: 56%)
Was obtained as an oil. The 1 H-NMR (400 MHz) spectrum data is as follows. (CDCl 3 , ppm): 4.72 (1H, d, J = 7.3Hz), 4.64 (1H, d, J = 7.3H
z), 3.95-3.91 (1H, m), 3.64-3.12 (9H, m), 3.60 (6H, s),
3.34 (3H, s), 2.86-2.83 (1H, m), 2.72-2.63 (1H, m), 1.95
(1H, d, J = 12.7Hz), 1.78-1.12 (11H, m), 1.20 (3H, s), 0.9
0 (2H, d, J = 12.2Hz), 0.86 (3H, s), 0.83 (3H, s), 0.79 (3H,
s).

【0070】応用例23 〇 ALB341の合成 ALB321の250mg(0.705mmol)及びジエタノール
アミン0.1ml(1.04mmol)を用い、ALB330とほぼ
同様の操作を行った。得られた残渣をシリカゲルカラム
クロマトグラフィー(SiO2:50ml,メタノール/クロ
ロホルム=4/96〜24/76)で精製し下記構造式で
示される化合物(以下ALB341という)247mg(収率:
76%)を油状物質として得た。その1H-NMR(400MHz)ス
ペクトルデータは以下のとおりである。 (CDCl3,ppm): 4.72(1H,d,J=7.3Hz), 4.64(1H,d,J=7.3H
z), 3.93-3.92(1H,m), 3.79-3.37(11H,m), 3.34(3H,s),
2.82-2.47(6H,m), 1.95(1H,dt,J=12.2,2.9Hz),1.78-1.
11(11H,m), 1.21(3H,s), 0.90(2H,dd,J=12.2,2.0Hz),
0.86(3H,s), 0.83(3H,s), 0.78(3H,s).
Application Example 23 Synthesis of ALB341 Using 250 mg (0.705 mmol) of ALB321 and 0.1 ml (1.04 mmol) of diethanolamine, the same operation as in ALB330 was performed. The obtained residue was purified by silica gel column chromatography (SiO 2 : 50 ml, methanol / chloroform = 4/96 to 24/76), and 247 mg of a compound represented by the following structural formula (hereinafter referred to as ALB341) (yield:
76%) as an oil. The 1 H-NMR (400 MHz) spectrum data is as follows. (CDCl 3 , ppm): 4.72 (1H, d, J = 7.3Hz), 4.64 (1H, d, J = 7.3H
z), 3.93-3.92 (1H, m), 3.79-3.37 (11H, m), 3.34 (3H, s),
2.82-2.47 (6H, m), 1.95 (1H, dt, J = 12.2,2.9Hz), 1.78-1.
11 (11H, m), 1.21 (3H, s), 0.90 (2H, dd, J = 12.2,2.0Hz),
0.86 (3H, s), 0.83 (3H, s), 0.78 (3H, s).

【0071】[0071]

【化24】 Embedded image

【0072】応用例24 〇 ALB342の合成 ALB321の250mg及びD-グルコサミン塩酸塩228m
gを用い、ALB330とほぼ同様の操作を行った。得られ
た残渣をシリカゲルカラムクロマトグラフィー(SiO2:
50ml,メタノール/クロロホルム=4/96〜16/8
4)で精製し下記構造式で示される化合物(以下ALB34
2という)284mg(収率:76%)を油状物質として得
た。その1H-NMR(400MHz)スペクトルデータは以下のとお
りである。 (CDCl3,ppm): 5.99(1H,dd,J=6.8,4.9Hz), 4.70(1H,d,J=
7.3Hz), 4.64(1H,d,J=7.3Hz), 4.53-4.41(1H,m), 3.64-
3.28(13H,m), 3.33(3H,s), 1.95(1H,dt,J=12.2,3.4Hz),
1.78-1.07(11H,m), 1.19(3H,s), 0.90(2H,d,J=12.2H
z), 0.86(3H,s), 0.81(3H,s), 0.78(3H,s).
Application Example 24 Synthesis of ALB342 250 mg of ALB321 and 228 m of D-glucosamine hydrochloride
Using g, the same operation as in ALB330 was performed. The obtained residue is subjected to silica gel column chromatography (SiO 2 :
50 ml, methanol / chloroform = 4/96 to 16/8
4) and purified by a compound represented by the following structural formula (hereinafter ALB34)
284 mg (Yield: 76%) was obtained as an oil. The 1 H-NMR (400 MHz) spectrum data is as follows. (CDCl 3 , ppm): 5.99 (1H, dd, J = 6.8,4.9Hz), 4.70 (1H, d, J =
7.3Hz), 4.64 (1H, d, J = 7.3Hz), 4.53-4.41 (1H, m), 3.64-
3.28 (13H, m), 3.33 (3H, s), 1.95 (1H, dt, J = 12.2,3.4Hz),
1.78-1.07 (11H, m), 1.19 (3H, s), 0.90 (2H, d, J = 12.2H
z), 0.86 (3H, s), 0.81 (3H, s), 0.78 (3H, s).

【0073】[0073]

【化25】 Embedded image

【0074】応用例25 〇 ALB343の合成 ALB321の250mg(0.705mmol)及びシス-2,6-ジ
メチルモルホリン0.11ml(0.89mmol)を用い、AL
B330とほぼ同様の操作を行った。得られた残渣をシリ
カゲルカラムクロマトグラフィー(SiO2:50ml,メタ
ノール/クロロホルム=1/99〜2/98)で精製し下記
構造式で示される化合物(以下ALB343という)を油状
物質として274mg(収率:83%)得た。その1H-NMR(4
00MHz)スペクトルデータは以下のとおりである。 (CDCl3,ppm): 4.72(1H,d,J=7.3Hz), 4.64(1H,d,J=7.3H
z), 3.92-3.87(1H,m), 3.72-3.63(2H,m), 3.57-3.50(1
H,m), 3.48-3.37(3H,m), 3.34(3H,s), 2.82-2.63(2H,
m), 2.47-2.32(2H,m), 2.01-1.93(2H,m), 1.78-1.09(12
H,m), 1.20(3H,s), 1.16(3H,s), 1.15(3H,s), 0.90(2H,
dd,J=12.2,2.0Hz), 0.86(3H,s), 0.82(3H,s),0.78(3H,
s).
Application Example 25 Synthesis of ALB343 Using 250 mg (0.705 mmol) of ALB321 and 0.11 ml (0.89 mmol) of cis-2,6-dimethylmorpholine,
Almost the same operation as in B330 was performed. The obtained residue was purified by silica gel column chromatography (SiO 2 : 50 ml, methanol / chloroform = 1/99 to 2/98), and 274 mg (yield) of a compound represented by the following structural formula (hereinafter referred to as ALB343) as an oily substance. : 83%). Its 1 H-NMR (4
(00 MHz) The spectrum data is as follows. (CDCl 3 , ppm): 4.72 (1H, d, J = 7.3Hz), 4.64 (1H, d, J = 7.3H
z), 3.92-3.87 (1H, m), 3.72-3.63 (2H, m), 3.57-3.50 (1
H, m), 3.48-3.37 (3H, m), 3.34 (3H, s), 2.82-2.63 (2H,
m), 2.47-2.32 (2H, m), 2.01-1.93 (2H, m), 1.78-1.09 (12
H, m), 1.20 (3H, s), 1.16 (3H, s), 1.15 (3H, s), 0.90 (2H,
dd, J = 12.2,2.0Hz), 0.86 (3H, s), 0.82 (3H, s), 0.78 (3H,
s).

【0075】[0075]

【化26】 Embedded image

【0076】応用例26 ○ ALB247の合成 ALB321(709mg)を脱水アセトニトリル(10ml)に
溶解し、4-ニトロイミダゾール(271mg)と無水過塩素
酸リチウム(426mg)を加え、室温で1日間攪拌した。
さらに、過塩素酸リチウム(410mg)を追加して加え、
60℃に加温しながら15時間攪拌した。反応溶液をク
ロロホルムと塩化アンモニウム水溶液に分液し、クロロ
ホルム層を飽和食塩水で洗浄し、無水硫酸ナトリウムを
加えて脱水した。水層をクロロホルムで抽出し、上記と
同様の処理を行った。これらをろ過後、合わせたろ液を
濃縮し、残渣をシリカゲルカラムクロマトグラフィにか
け、下記構造式で示される化合物(以下ALB247とい
う)を250mg得た(収率27%)。 ALB247の1H NMRデータ(DMSO-d6) δ 8.26(1H, s, -CH=), 7.76(1H, s, -CH=), 4.68(1H,
d, J= 7.33Hz, -O-CH-O-), 4.56(1H, d, J= 7.33Hz, -O
-CH-O-), 4.09(2H, m, -CH2-Triazole), 3.45-3.16(8H,
m, -CH2-O-CH2-, CH-OH and -O-Me), 1.91(1H, m, cyc
lic CH), 1.7-0.76(25H, m, cyclic CH and Me×4)
Application Example 26 Synthesis of ALB247 ALB321 (709 mg) was dissolved in dehydrated acetonitrile (10 ml), 4-nitroimidazole (271 mg) and anhydrous lithium perchlorate (426 mg) were added, and the mixture was stirred at room temperature for 1 day.
In addition, additional lithium perchlorate (410 mg) was added,
The mixture was stirred for 15 hours while heating to 60 ° C. The reaction solution was separated into chloroform and an aqueous solution of ammonium chloride, and the chloroform layer was washed with saturated saline and dehydrated by adding anhydrous sodium sulfate. The aqueous layer was extracted with chloroform, and the same treatment as above was performed. After filtration, the combined filtrate was concentrated, and the residue was subjected to silica gel column chromatography to obtain 250 mg of a compound represented by the following structural formula (hereinafter referred to as ALB247) (yield 27%). 1 H NMR data of ALB247 (DMSO-d6) δ 8.26 (1H, s, -CH =), 7.76 (1H, s, -CH =), 4.68 (1H,
d, J = 7.33Hz, -O-CH-O-), 4.56 (1H, d, J = 7.33Hz, -O
-CH-O-), 4.09 (2H, m, -CH 2 -Triazole), 3.45-3.16 (8H,
m, -CH2-O-CH 2- , CH-OH and -O-Me), 1.91 (1H, m, cyc
lic CH), 1.7-0.76 (25H, m, cyclic CH and Me × 4)

【0077】[0077]

【化27】 Embedded image

【0078】○ 化合物の特性測定 実施例3および応用例7〜26で合成された各化合物の
抗真菌活性および感染治療試験の結果を表5、表6に示
す。
測定 Measurement of compound properties Tables 5 and 6 show the results of the antifungal activity and infection treatment tests of the compounds synthesized in Example 3 and Application Examples 7 to 26.

【0079】[0079]

【表5】 [Table 5]

【0080】[0080]

【表6】 [Table 6]

【0081】[0081]

【発明の効果】以上の結果から、本発明の化合物は抗真
菌剤として、あるいは抗真菌剤製造のための原料として
有効な新規な化合物であることが示される。
The above results show that the compound of the present invention is a novel compound effective as an antifungal agent or as a raw material for producing an antifungal agent.

【図面の簡単な説明】[Brief description of the drawings]

【図1】 HAL-1の1H−NMRチャートである。FIG. 1 is a 1 H-NMR chart of HAL-1.

【図2】 HAL-1の13C−NMRチャートである。FIG. 2 is a 13 C-NMR chart of HAL-1.

【図3】 HAL-3の1H−NMRチャートである。FIG. 3 is a 1 H-NMR chart of HAL-3.

【図4】 HAL-3の13C−NMRチャートである。FIG. 4 is a 13 C-NMR chart of HAL-3.

【図5】 HAL-4の1H−NMRチャートである。FIG. 5 is a 1 H-NMR chart of HAL-4.

【図6】 HAL-5の1H−NMRチャートである。FIG. 6 is a 1 H-NMR chart of HAL-5.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) C07C 41/28 C07C 41/28 43/196 43/196 49/323 49/323 // C07C 62/12 62/12 (72)発明者 若山 敏之 茨城県つくば市大久保2番 東亞合成株式 会社つくば研究所内 (72)発明者 小池 信明 茨城県つくば市大久保2番 東亞合成株式 会社つくば研究所内 (72)発明者 瀬川 俊章 茨城県つくば市大久保2番 東亞合成株式 会社つくば研究所内 (72)発明者 野副 重男 宮城県仙台市太白区八木山本町一丁目10番 4号 Fターム(参考) 4C206 AA03 CA26 CB24 MA01 ZB26 ZB35 4H006 AA01 AB20 AB84 BJ30 BN20 BP10 ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat ゛ (Reference) C07C 41/28 C07C 41/28 43/196 43/196 49/323 49/323 // C07C 62/12 62 / 12 (72) Inventor Toshiyuki Wakayama 2nd Okubo Tsukuba, Ibaraki Pref.Toagosei Co., Ltd.Tsukuba Research Laboratories (72) Inventor Nobuaki Koike 2nd Okubo Tsukuba City Ibaraki Pref. Toshiaki 2nd Okubo Tsukuba, Ibaraki Pref. Toagosei Co., Ltd. Tsukuba Research Laboratories (72) Inventor Shigeo Nozoe 1-10-4 Yagiyama Honcho, Taishiro-ku, Sendai-shi, Miyagi 4F F-term (reference) 4C206 AA03 CA26 CB24 MA01 ZB26 ZB35 4H006 AA01 AB20 AB84 BJ30 BN20 BP10

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】 下記構造式で示されるヒドロナフタレン
誘導体。 【化1】 ただし、式中XとYは低級アルキル基と置換基または保
護基を有していてもよい水酸基であるか、XYの合一し
た形の保護基を有していてもよいカルボニル基であり、
mとnは3までの整数である。
1. A hydronaphthalene derivative represented by the following structural formula. Embedded image However, in the formula, X and Y are a lower alkyl group and a hydroxyl group which may have a substituent or a protecting group, or a carbonyl group which may have a protecting group in the unified form of XY,
m and n are integers up to 3.
JP11197344A 1999-07-12 1999-07-12 Hydronaphthalene derivative Pending JP2001026564A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP11197344A JP2001026564A (en) 1999-07-12 1999-07-12 Hydronaphthalene derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11197344A JP2001026564A (en) 1999-07-12 1999-07-12 Hydronaphthalene derivative

Publications (1)

Publication Number Publication Date
JP2001026564A true JP2001026564A (en) 2001-01-30

Family

ID=16372925

Family Applications (1)

Application Number Title Priority Date Filing Date
JP11197344A Pending JP2001026564A (en) 1999-07-12 1999-07-12 Hydronaphthalene derivative

Country Status (1)

Country Link
JP (1) JP2001026564A (en)

Similar Documents

Publication Publication Date Title
US9850254B2 (en) Synthetic process for preparation of macrocyclic C1-keto analogs of Halichondrin B and intermediates useful therein including intermediates containing-SO2-(p-tolyl) groups
Zurwerra et al. Total synthesis of (−)‐zampanolide and structure–activity relationship studies on (−)‐dactylolide derivatives
JP2003515601A (en) Bryostatin analogs, synthetic methods and uses
Kikuchi et al. Structural requirements of dictyopyrones isolated from Dictyostelium spp. in the regulation of Dictyostelium development and in anti-leukemic activity
US20170291905A1 (en) Arginine methyltransferase inhibitors and uses thereof
JP2004509972A (en) Triterpenes with fungicidal activity against yeast
JPH0352458B2 (en)
Jayasuriya et al. Barceloneic acid A, a new farnesyl-protein transferase inhibitor from a Phoma species
Reddy et al. Total synthesis and in vitro bioevaluation of clavaminols A, C, H & deacetyl clavaminol H as potential chemotherapeutic and antibiofilm agents
FI91960B (en) Process for the preparation of octahydronaphthalene oxime derivatives useful as pharmaceuticals
JP2713561B2 (en) Tetrahydropyran derivative
US9670247B2 (en) Contraceptive agents
Chakraborty et al. Synthesis of (+)-prelactone B
JP2001031663A (en) Epoxy compound and its derivative
JP2001026564A (en) Hydronaphthalene derivative
EP0350164A2 (en) Amphotericin derivatives
Sugahara et al. First stereoselective synthesis of meso-secoisolariciresinol and comparison of its biological activity with (+) and (−)-secoisolariciresinol
JP2002179564A (en) Antifungal agent
JP2001048873A (en) Epoxy compound and its derivative
JP2001048841A (en) Hydronaphthalene derivative and its amide compound
JP2001039923A (en) Hydronaphthalene derivative
JP2001097925A (en) Hydronaphthalene derivative and its amide compound
JP2001097855A (en) Antifungal agent
JP2001081052A (en) Epoxy ring opened compound
JP2001114721A (en) Hydronaphthalene derivative